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Abstract 
Breast cancer is considered the most common cancer among females in developed and developing 
countries. Previously, it was reported that the 5-year survival for breast cancer in the Gaza Strip 
did not exceed 30-40% and one of the factors is the diagnosis at advanced stages. This study aimed 
to evaluate the utilized diagnostic imaging modalities for breast cancer in the Gaza Strip in order 
to examine factors affecting the provision of timely and accurate diagnosis. 
Retrospective cross-sectional triangulated study design was used.Quantitative data were collected 
through two instruments; the first was interviewed questionnaire filled with 122 newly diagnosed 
breast cancer women registered at one of the two main oncology centers in the Gaza Strip, andthe 
other was an abstraction sheet to collect data from the patients' medical files. Qualitative data were 
collected through thirteen in-depth interviews with various medical specialists. 
 The study revealed that there is underutilization ofmammography screening programs that the 
majority of women seeking health care only after a mass have been felt. Moreover, the study showed 
that women face some barriers to seek health care. These barriers were mainly attributed tolack of 
awareness about the symptoms. The study also showed that patients perceived high overall 
accessibility scores regarding mammography, Ultrasound, and biopsy which were 82%, 80%, 78% 
respectively. In addition, the study showed 19.7% of women delayed in seeking health care three 
months and more.  
The study revealed that there is no a national standard protocol to diagnose breast cancer in the 
Gaza Strip. Mammography and Ultrasoundwere the most commonly usedimaging methods for breast 
cancer diagnosis. Undoubtedly, the confirmation of diagnosis was done by biopsy. The majority of 
patients (93.4 %)were referred to imaging diagnosis within 2 weeks of seeking health care. Notably, 
12.3% of patients have a diagnosticdelay three months and more. Regarding the effectiveness of 
imaging methods, mammography and Ultrasoundweresucceeded to diagnose 84.1 %, 93.1% 
respectivelyof the referred cases and the majority of their reports were written without using a 
standard classification. In addition, the study revealedthatfactors affecting patient delay were mainly 
related to unawareness about the symptoms of breast cancer. Regarding to diagnostic delay, the 
study showed that the diagnostic delay was affected by patient age, nonmalignant findings in either 
mammography or Ultrasound. 
The study recommends adoption of acomprehensive national program to educate and screen women, 
tofollow up and diagnose breast cancer patients underthe supervision of Ministry of Health and the 
necessary to put in place the required guidelines for each step in order to guarantee the provision of 
early and accurate diagnosis of breast cancer. 
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  "حقُُى خذياث انخصىَر انخشخُصُت انًخاحت نذي يرضً سرطاٌ انثذٌ فٍ يحافظاث قطاع غزة" 
يهخص انذراست 
ٚفٟ رمش٠ش عبثك ٌٕبِ١خ ٚاٌّزمذِخ، ا إٌغبء فٟ اٌجٍذاْ ِدزّغ٠ؼزجش عشؽبْ اٌثذٞ ٘ٛ الأوثش ش١ٛػب ًث١ٓ
-03عٕٛاد ػٍٝ ل١ذ اٌس١بح ٌذٜ إٌغبء اٌّظبثبد ثغشؽبْ اٌثذٞ فٟ لطبع غضحلا ٠ض٠ذ ػٓ 5ِؼذي اٌجمبء وبْ
. ٚلذ فغشعجت رذٟٔ ٘زٖ إٌغجخ ثؼٛاًِ أزذُ٘ ٠شخغ إٌٝ رشخ١ض اٌّشع فٟ ِشازً ِزأخشح% 04
انهذف يٍ انذراست 
 ٌذساعخ اٌؼٛاًِ اٌزٟ  فٟ لطبع غضح٘ذفذ اٌذساعخإٌٝ رم١١ُ خذِبد اٌزظٛ٠ش اٌّزبزخ ٌّشػٝ عشؽبْ اٌثذٞ
ة ِٓ أخً رسغ١ٓ اٌخذِبد اٌزشخ١ظ١خ ح دل١مخ ٚفٟ اٌٛلذ إٌّبطٞرؤثش ػٍٝ رمذ٠ُ خذِبد رشخ١ض
 . ٌٍّشػىِٛٓ ثُ ص٠بدح ِؼذلاد اٌجمبء ػٍٝ ل١ذ اٌس١بح
يُهجُت انذراست 
عزخذاَ ٚع١ٍز١ٓ ٌدّغ اةاٌىّ١خ,  ٚ ٔٛػ١خاٌذساعخ ػجبسح ػٓ دساعخ رسٍ١ٍ١خ شٍّذ ػٍٝ خّغ ث١بٔبد وّ١خ
 7102 خلاي عٕخ ْثذٞ رُ رشخ١ظٗايعشؽبْ ة ِش٠ؼخ221الأٌٚٝ ٟ٘ إعزجبٔخ رُ رؼجئزٙب ِغ , اٌج١بٔبد
خّغ اٌج١بٔبد ٜ ٟ٘ ِٚزبثؼبد فٟ ِشاوض أٚساَ ِغزشفٝ ػجذ اٌؼض٠ض اٌشٔز١غٟ ٚغضح الأٚسٚثٟ، اٌٛع١ٍخ الأخش
ثبٌٕغجخ ٌٍّؼٍِٛبد إٌٛػ١خ رُ خّؼٙب .  ٚاٌزٛاطً اٌشخظٟ ِغ اٌّش٠ؼخاٌلاصِخ ٌٍذساعخ ِٓ ٍِفبد اٌّشػٝ
 ٚاٌز٠ٓ ٠شبسوْٛ فٟ ػٍّ١خ رشخ١ض عشؽبْ اٌثذٞ الأخظبئ١١ٓ ِمبثٍخ شخظ١خ ِغ ِخزٍف 31ِٓ خلاي 
. ٚ أؽجبء اٌشػب٠خ الأٌٚ١خ )ػٍُ الأٔغدخ- الأشؼخ- اٌدشازخ- الأٚساَ(ٞ ّٞٚ٘أخظبا
 ٚلذ رُ ػًّ خذاٚي اٌزشدداد )SSPS(رُ رسٍ١ً ث١بٔبد اٌذساعخ ثئعزخذاَ ثشٔبِح اٌزسٍ١ً الإزظبئٟ 
ٚاٌشعِٛبد اٌج١بٔ١خ اٌّخزٍفخ ٚأ٠ؼب ًرُ ػًّ اٌفسٛطبد الإزظبئ١خ اٌّخزٍفخ لإ٠دبد ػلالبد ث١ٓ اٌّزغ١شارجٙذف 
 ثٙذف اٌّغر أظٙشد اٌذساعخ أْ إٌغبء فٟ لطبع غضح لا ٠زٛخٙٓ إٌٝ ثشاِح اٌّغر.رسم١ك أ٘ذاف اٌذساعخ
 رٛخٙٓ ٌٍفسض ثؼذ  ػ١ٕخ اٌذساعخ لذ ِٓ أخً اٌزشخ١ض ز١ث أْ اٌؼذد الأوجش ٌِٓٙزٖ اٌجشاِح٠زٛخٙٓ ٌٚىُٕٙ
أوثش . ِٚٓ ٔزبئح اٌذساعخ أ٠ؼب ًأْ إٌغبء ٠ٛاخٙٓ ِؼ١مبد رسٛي دْٚ اٌٛطٛي ٌٍخذِخ . الإزغبط ثٛخٛد وزٍخ
 أ٠ؼب ًاٌزظٛ٠ش اٌغبثك اٌزٞ أعفش ػٓ , اٌفُٙ اٌد١ذ لأػشاع ٚػلاِبد اٌغشؽبَْ٘زٖ اٌّؼ١مبد ِزؼٍمخ ثؼذ
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ٚخذد اٌذساعخ أْ .  ِشح أخشٜ٠خٌزشخ١ضٌخذِبد ا ياٌغ١ذادٔزبئح عٍج١خ ٌٛخٛد اٌغشؽبْ شّىً ػبئمب ًٌٍدٛء
أٌزشاعبٚٔذ، ػ١ٕخ , ٌخذِبد اٌزشخ١ظ١خ ِبِٛخشاَ ٚاٌسظٛي ػٍىبٚطٛيِؼذلاد ايػبد وبْ ٌذ٠ُٙ ٞاٌّش
ِٓ إٌغبء ٌذ٠ُٙ رأخ١ش ٌٍؼشع ػٍٝ  7.91%ٚخذد اٌذساعخ أ٠ؼب ًأْ. ػبٌزٛاٌٟ% 87%,08%,28دثّؼذلا
.   شٙٛس فّب فٛق3الأخظبئ١١ٓ ثؼذ ظٙٛس الأػشاع 
٠ؼزّذ ٚ,ح ٌزشخ١ض ِشػٝ عشؽبْ اٌثذٞ فٟ لطبع غض ٚؽٕٟ اٌذساعخ ٌ١ظ ٕ٘بن ثشٚرٛوٛي ل١بعِٟٚٓ ٔزبئح
ٚ ٠زُ رأو١ذ  أٚ وٍ١ّٙبالأٌزشاعبٚٔذأٚ )اٌّبِٛخشاَ (فسض اٌثذٞ ثبلأشؼخ ٜ اٌزشخ١ض ثشىً أعبعٟ ػً
 ِٓ اٌغ١ذاد رُ رسٛ٠ٍُٙ ٌٍزظٛ٠ش % 4.39. اٌزشخ١ض إٌٙبئٟ ثغست اٌؼ١ٕخ ٌ١زُ فسظٙب ثّخزجشاد الأٔغدخ
ِٓ اٌغ١ذاد اٌّشخظبد ٚاخٙٓ  3.21%ٚخذد اٌذساعخ أ٠ؼب ًثأ  ّْ. خلاي أعجٛػ١ٓ ِٓ ؽٍت اٌشػب٠خ اٌظس١خ
 ثبٌٕغجخ ٌفبػٍ١خ فسٛطبد رشخ١ض عشؽبْ . شٙٛس ٚأوثش ِٓ ؽٍت اٌشػب٠خ اٌظس١خ3رأخ١ش فٟ رشخ١ظُٙ 
إٌ١ٗ ث١ّٕب ِٓ اٌسبلاد اٌّسٌٛخ %48 رشخ١ض اعزطبعاٌثذٞ، ٚخذد اٌذساعخ أْ اٌّبِٛخشاَ
ِٓ اٌسبلاد اٌّسٌٛخ إٌ١ٗ ِغ ِلازظخ أ ّْ ِؼظُ رمبس٠ش اٌزظٛ٠ش ُوزجذ %39 رشخ١ض ٔذالأٌزشاعبٚاعزطبع
 ثؼذ ؽٍت اٌشػب٠خ ٚخذد اٌذساعخأْ اٌؼٛاًِ اٌزٟ رؤدٞ اٌىزأخش اٌزشخ١ض.ثذْٚ اعزخذاَ رظٕ١ف ل١بعٟ ِٛزذ
 .  ٟ٘ اٌؼّش ٚٔزبئح اٌّبِٛخشاِٛالأٌزشاعبٚٔذغ١ش اٌظس١سخِغ ٚخٛد دلالاد إزظبئ١خ ػٍٝ رٌهاٌظس١خ
رشخ١ض ِٚزبثؼخ زبلاد , ٌؼًّ ِغر, رٛطٟ اٌذساعخ ثؼشٚسح ٚخٛد ثشٔبِح ٌغشؽبْ اٌثذٞ ٌزٛػ١خ اٌغ١ذاد
رسذ إششاف ٚصاسح اٌظسخ ٚػشٚسح اٌؼًّ ػٍٝ ٚػغ خطٛؽ ػش٠ؼخ ٚإعزشار١د١بد , عشؽبْ اٌثذٞ
ِٛزذح ٠ٍزضَ ثٙب اٌدّ١غ ٚرىْٛ ِٛزذح ػٍٝ ِغزٜٛ اٌٛؽٓ ٚرٌه ٌؼّبْ رمذ٠ُ خذِبد رشخ١ظ١خ دل١مخ ٚ فٟ 
 .اٌٛلذ إٌّبعت
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Chapter1: Introduction 
1.1 Background 
Breast cancer (BC) is considered a major health problem andthe most common cancer 
among females in both developed and non-developed countries.If BC is diagnosed early, 
more specific and less aggressive therapy options are possible, and mortality frombreast 
cancer falls. 
BC incidence was previously measured to be 1.67 million new cases worldwide,and was 
responsible for approximately 522,000 deaths in 2012 (Ferlay et al., 2015). In spite of 
considering BC to be a disease of the developed world,Ferlayand Colleagues(2010) 
showed that roughly 50% of all BC deaths in the world occurred in developing countries 
during the year 2008. These deaths were attributed to diagnosis in more advanced stages 
(Unger-Saldana, 2014). It was reported that the age-standardized incidence rate (ASR) of 
breast cancer in Asia 29.1/100,000, USA 92.9/100,000 and 94.2/ 100000 in Europe. 
However, the mortality to-incidence ratios are much higher 0.35 for Asia in comparison to 
0.16 for USA (Bridges et al., 2011) and 0.24 for Europe(Ferlay et al., 2013).  
In Palestine, according to Ministry of Health(MOH), there were 388 new cases in the West 
Bank during the year 2016 constituting around 15.3% of all cancercases (MOH, 2017). 
According to cancer registry in Gaza Governorates (GGs), there were 684 cases during the 
year 2016 constituting around 20.5% of all cancer cases (MOH, 2016) 
Early diagnosis of BC is defined by World Health Organization (WHO) as early 
identification of patients with symptoms ofBC without delay; patients with cancer should 
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receive diagnostic examinations, pathological confirmation and staging procedures at an 
appropriate diagnostic facility (WHO, 2017).  
Internationally, there are various diagnostic techniques and image-guided interventional 
procedures used for BC diagnosis. Mammography, Ultrasound (U/S) and Magnetic 
Resonance Imaging (MRI) are the most widely used modalities in breast imaging.  
Mammography is considered to be the gold standard in screening(Fletcher and Elmore, 
2003; Tabár et al., 2001),U/Sis effective in detecting lesions and differentiating a benign 
lesion from malignant one and the combination of both examinations can diagnose breast 
tumors more accurately (Houssami et al., 2003; Benson et al., 2004; Mujagic et al., 2011). 
This study is the first study in GGs aimed to evaluate the role of diagnostic imaging tools 
for BC in terms of effectiveness, timely diagnosis and barriers that may hinder the success 
of this process. 
1.2 Research Problem 
It was reported that 5- year survival rate of BC patients in the GGswas 30- 40% and one of 
the causes of this low rate is a deficit in the final diagnosis (Bendel et al, 2005). Another 
study, reported it to be 53.4%(Alagha, 2014).In comparison, 5- year survival rate for BC 
varies in different countries that it was reported to be 59.6% in Saudi Arabia 
(Ravichandran et al., 2005), 70% in Iran (Fallahzadeh et al., 2014), 66% to 76% in Spain, 
74% in France, 82% in Italy and Netherlands(Sant et al., 2004). 
Also, it had been reported that BC among Palestinian women presents in advanced stages 
of the disease. Around 42.2% of reported cases had regional lymph-node involvement 
(stage III) and 17.8% had distant metastases (stage IV)(Hussein et al., 2009).  
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A systematic review of Unger-Saldana (2014) showed that the lower BC survival rates 
observed for developing countries in comparison to developed countries are due to 
diagnosis in much more advanced stages. Such delayed diagnosis may berelated to co-
factors that patient, community, and health care system share.  
1.3 Justification 
Cancer early diagnosis is defined by WHO as the early identification of cancer in patients 
who have symptoms of the disease(WHO, 2017). In the same report, WHO reported that 
the likelihood of morbidity, disability, and mortality increase as the cancer progress (ibid). 
In countries such Palestine when there is a scarcity of resources, the first priority is to have 
in place accurate diagnosis and to detect tumors at earlier stages without delay in order to 
initiate early and timely diagnosis that help patients with cancer to start their treatment 
early and to decrease anxiety among those diagnosed as free of BC.  
In the Gaza Strip, there is no formal policy for screening mammography to all 
asymptomatic women at certain age and no generalized guidelines on the best time to do a 
screening mammography. However, there are several fragmented non-permanent screening 
mammography programsexecuted by several providers; MOH, some Nongovernmental 
Organizations (NGOS), United Nations Relief and Work Agencies for Palestine Refugees 
in the Near East (UNRWA). Unfortunately, the benefits of these programs and to what 
extent they effective in BC diagnosis are not studied yet in GGs. 
Several studies conducted to evaluate the screening mammography services and the 
barriers that hinder women to conduct the screening mammography(Shaheen et al., 2011; 
Abu-Shammala and Abed, 2015; Jadallah, 2016). Other previous related studies focused on 
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the prevalence of cancer, determinants of5- year survival rate and factors affecting quality 
of life among those patients. There is a gap in research about the effectiveness of imaging 
modalities in BC diagnosis, time required to diagnosis, and barriers affecting the success of 
the process. Hence, it will be rational to conduct a scientific research with an aim to 
evaluate the diagnostic imaging modalities for BC in the GGs regarding accurate and 
timely diagnosis. This will help decision makers to identify the gaps in the imaging 
diagnostic services in order to improve them.  
In addition, the results of the current study will be beneficial for the BC patients that it may 
help to improve the weaknesses points in the diagnosis process, thus increasing patient's 
survival rate, decrease morbidity and mortality.  
Also, for the researchers, the study is the first one and will be the milestone for others to 
open many fields for research especially in the field of false negative and false positive 
results of imaging diagnostic services that have an effect on the cancer patients and healthy 
women as well.Therefore, this study attempts to evaluate imaging diagnostic methods used 
to diagnose BC and factors affecting the provision of rapid and accurate BC diagnosis. 
1.4 Study Objectives 
1.4.1 General Objective 
This study evaluates the utilized imaging modalities (Mammography, Ultrasound, and 
Magnetic Resonance Imaging) for BC diagnosis in the Gaza Strip in order to enhance early 
diagnosis of BC and increase survival rate. 
1.4.2 Specific objectives 
 To investigate the effectiveness of imaging modalities to diagnose BC using 
histopathology report as a reference. 
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 To categorize patients perceived barriers that may hinder early diagnostic process. 
 To examine the relationship between patients' accessibility to different diagnostic 
examinations andthe utilizedsectors. 
 To identify factors that may affect the early diagnosis ofbreast cancer. 
1.5 Study Questions 
 To what extent mammography and U/S are effective todiagnose BC in GGs? 
 Is there a difference in mammography and U/S reports in their initial diagnosis of 
breast cancer? 
 Do doctors depend on a standard protocol when they refer suspected BC to imaging 
modalities? 
 What are the scores of patients' accessibility domains regarding different diagnostic 
exams? 
 Is there a difference between patients' accessibility scores with regards to the sector 
they utilized? 
 What are the main barriers that patients face when they decide to seek health care after 
BC symptoms appeared? 
 What are the main sources of delay in BC diagnosis? 
 Is there a significant difference between time delay in diagnosis and patients 
characteristic variables (Age, Place of residence, income level of education, presence 
of family history)? 
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1.6 Context of the study 
1.6.1 Gaza Governorate demographic characteristics 
Palestine is a small country in its area (26.323Km
2
). It has an important geographic 
location (Annex1);it is located in the East of the Mediterranean Sea in the Middle 
East,boarded by Syria and Jordan from the east, Lebanon from the north, Golf of Al Aqaba 
from the south and by Egypt and the Mediterranean Sea from the west. Palestinian 
National Authority (PNA) controls two geographically separated areas, West Bank and 
Gaza Strip. Population density in Palestineis 811 (Capita/km
2
) in the end of the year 2016, 
for the west bank is 519 and for GGs is 5154.  
GGsis a small piece of land located in the southern area of Palestine, according to 
Palestinian Central Bureau of Statistics (PCBS), there were 1,800,000 Inhabitants in the 
mid-year 2016(PCBS, 2016a). It is divided into five governorates: North Gaza, Gaza City, 
Mid Zone, Khanyounis and Rafah(Annex 2).  
1.6.2 Palestinian health care system 
Health care system plays an important role in improving health. Well-functioning health 
system enables achievement of good health with efficient use of available resources (Atun, 
2012). In the GGs, health care services are provided mainly through four sectors, 
governmental health services at MOH, NGOs, UNRWA, and the Private Sector. 
 MOH provides primary, secondary, and tertiary health services and purchase the 
unavailable tertiary health services from domestic and abroad providers. UNRWA 
provides primary care services and purchase secondary care services for refugees. NGOs 
provide primary, secondary and some tertiary services. Private for-profit sector provides 
the three level of care through a variety of specialized hospitals and investigation centers.  
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The fragmentation in the health care system and the lack of coordination between various 
sectors increase the challenges to provide optimal health care services. 
1.6.3 Noncommunicable diseases 
Noncommunicable diseases (NCDs) including heart disease, stroke, cancer, diabetes and 
chronic lung diseases are responsible for almost 70% of all deaths worldwide. Almost three 
quarters of all NCDsdeaths and 82% of the 16 million people who died prematurely occur 
in low- and middle-income countries(WHO, 2011).  
The rise of NCDs has been driven by primarily four major risk factors: tobacco use, 
physical inactivity, the harmful use of alcohol and unhealthy diets (ibid). MOH in the 
GGshas reported that the number of NCDs patients registered in the primary health care 
(PHC) centers were 34026 patients, of them 3.3 % are cancer patients (MOH, 2015a) 
1.6.3.1 Cancer 
According to cancer registry in GGs, 7069 new cancer cases registered during the period 
2009- 2014(MOH, 2015b).The most common cancer among female population in the GGs 
is BC. In the other hand, the most common cancer among males is colon cancer 
constituting around 11.5% of male cancers (ibid). 
1.6.3.2 Breast cancer Services 
BC diagnosis starts when the patient seekshealth care and this may be at PHC, 
governmental hospitals, NGOs, private sector and even UNRWA. The patient then is 
referred to a specialist or imaging center to start the diagnostic journey. 
After confirmation of the diagnosis, mostly the patient will register in one of the two 
oncology centers (Al-Rantesihospital or Gaza European hospital) for treatment and follow 
up. 
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Al- Rantisi hospital 
Al- Rantisi Specialized Pediatric hospital is the only governmental specialized Pediatric 
hospital in GGs. It is considered as a secondary health care delivery organization. The 
hospital has been established in 2003 on an area of over 2500 m
2
, and had become ready to 
work in 2006.  
The hospital provides health care for patients less than 12 years old since that date, and 
recently it provides health services for the adult oncology and hematology patients after the 
department had been transferred from Al Shifa hospital to it since 2016 (MOH, 2012 a). 
Department of oncology and hematology at the hospital is divided into two main parts, the 
outclinic& daily care unit, and the inpatient department.  
The staff of the department consists of 4 oncologists, 5 hematologists, 3 pharmacists, 3 
administrative workers, and 19 nurses (Zaggout, September 2017, Personal 
communication). 
Regarding beds, there were 14 beds for women, 10 beds for men in the daily care, while 
the total number of beds at the inpatient department is 30 beds for women and men (ibid). 
The daily care unit provides treatment and a wide range of special support services for BC 
patients on Sunday, Monday, and Wednesday of every week. Patients attend the daily care 
unit for a medical or nursing review, blood tests, procedures or treatments, including 
chemotherapy.  
On arrival, patient will be greeted by reception and asked to confirm personal 
details.Then,patients meet the triage nurse who will record weight and height and withdraw 
a blood sample. It may take 30 to 40 minutes for blood results to be ready. Then it will be 
seen by the doctor or nurse in order to decide if the patient will receive treatment or not 
(ibid). 
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Gaza European hospital  
Gaza European hospital is located at the southern governorate of Khanyounis on a land 
area 65 Dunums. It was built in 1993 and is considered one of the main hospitals in the 
southern area providing secondary and tertiary services. Initially, the hospital was 
established through UNRWA and funded by the European cooperation. In 1997 the 
hospital began to operate after agreement between European Union, PNA and UNRWA 
and then the real work started at 2000 when the first case was admitted to the hospital. 
The hospital departments were later established until the emergency department was 
completed in March 2001.Today, the total number of bed reaches 256 beds, and the total 
number of employees is 765("Gaza European Hospital in Numbers", 2016). 
 Cancer services are provided for Khanyounis and Rafah inhabitants through the 
department of oncology and hematology. The department is divided into inpatient unitfor 
admitted cases and outpatient's  clinics fordaily care and follow up for the patients 12 years 
old and more (MOH, 2012 b).Working days for daily care oncology in the outpatient's 
clinics were Sunday, Tuesday. In addition Wednesday is considered a day for follow up of 
cases at the outclinic(Afanah, September 2017, Personal communication). 
The staff of the department consists of 4 oncologists and 5 hematologists for the two parts, 
26 nurses- of them 4 nurses are working at daily care and 2 at outclinic unit (ibid).  
Regarding beds, there were 9 beds and 21 chairs in the daily care, while the total number 
of beds at the inpatient department is 29 beds for women and men (ibid). 
During the year 2016, 153 cases were admitted to the oncology and hematology 
department. In addition, there were 7400 patients visits and 5000 chemotherapy sessions 
were provided in the outclinicunit ("Gaza European Hospital in Numbers",2016). 
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1.7 Operational definitions 
1.7.1 Potential delay 
Total delay: Suspected BC patient should complete the diagnosis within 90 days (3 
months) of symptoms appearance according to WHO cancer early diagnosis guide (WHO, 
2017). In this study, total delay is the summation of patient delay and diagnostic delay.  
Patient delay: is a delay in seeking medical counseling after self-discovering a potential 
BC symptom (Caplan, 2014). In the current study, the researcher defined the patient delay 
as those who have been delayed 3 months andmore to seek medical counseling after BC 
symptoms appeared. 
Diagnostic delay: is the delay within the health care system in getting appointments, 
scheduling diagnostic tests, receiving a definitive diagnosis and initiating therapy (Unger-
Saldana, 2014). 
In this study, the researcher considered the diagnostic delay as a delay 3 months andmore 
from the first counseling visit to confirmation of diagnosis.Also, the researcher divided the 
diagnostic delay into parts to identify the most important points causing delay. 
Referral delay:A referral is defined as a process in which a health care provider at one 
level of the health system- having insufficient resources (drugs, equipment, skills) to 
manage a clinical condition- seeks the assistance of a better or differently resourced facility 
at the same or higher level to assist in (Goel et al., 2013).  
It was previously reported by National Cancer Control Programme (NCCP) that the 
suspected BC patients should be referred to diagnosis within 2 weeks from the first 
medical counseling(NCCP, 2012). The researcher defined the referral delay as a delay 
more than 14 days required for the patient to be referred from the first counseling visit. 
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Mammography delay: is the time delay more than 7 days (including appointment) to 
conduct mammography and getting results. 
U/S delay: is the time delay more than 7 days (including appointment)to conduct U/S and 
getting results. 
Biopsy delay:time delay more than 14 days from imaging resultsto perform the biopsy. 
Histopathology delay: time delay more than 14 days frombiopsy (sampling) and getting 
the first histopathology report confirmed malignancy (Time elapsed in the histopathology 
department). 
1.7.2 Imaging method of choice 
The appropriate imaging should be carried out for patients suspected to have BC in the 
following criteria; U/S is the imaging method of choice for the majority of women aged < 
40 years and during pregnancy and lactation, and mammography is used in the 
investigation of women aged ≥40 years with the addition of U/S when it is indicated 
(Willett et al., 2010). 
In the current study, the researcher examined imaging method of choice in the BC initial 
diagnosis and to what extent physicians follow international standards.  
1.7.3 Barriers 
Barrier in health care is defined as a person's estimation of the level of challenge of social, 
personal, environmental, and economic obstacles to a specified behavior or their desired 
goal status on that behavior (Glasgow, 2008). 
In the current study, barrier is any obstacle face the patient and prevent her receiving 
timely and accurate diagnosis of BC including, lack of knowledge about BC symptoms, 
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fear of cost related to exams and transportation, difficulties in referral to imaging, absence 
of health insurance, geographical, a previous doctor visit or imaging, culture, fear of 
results, and difficulties in getting appointments, The study examines barriers that may be 
related to health care system, and to the patients as well. 
1.7.4 Accessibility 
Access to health care remains a complex concept as it was interpreted by various 
descriptions through authors. Access was defined as a way of approaching, reaching or 
entering a place, as the right or opportunity to reach, use or visit (Stevenson, 2010). 
In the current study, the researcher studied accessibility considering three main domains: 
physical accessibility &affordability domain, waiting time & appointments domain, and 
communication & patient respect domain. 
1.7.5 Accurate results 
Diagnostic accuracy relates to the ability of a test to discriminate between the target 
condition and health (Simundic, 2009). In this study, in order to investigate errors in 
mammography and U/S reports and because of lack of information about the follow up 
process, a comparison between the report of each imaging exam (mammography or U/S) 
with the histopathology report as a reference was made, and between the reports of the two 
different imaging exams were also made. The researcher considered suspected and highly 
suspicious of malignancy results in mammography and U/S as accurate results. Regarding 
reported benign lesions, dense breast for other investigations and normal studies were 
considered as not accurate results. 
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Chapter2: Conceptual framework and literature review 
2.1 Conceptual framework 
The researcher drew the conceptual framework based on the literature review and personal 
experience. This framework shows what the researcher is going to study. The current study 
examines three main parts that may affect BC diagnosis.  
The first part is the patient factors including sociodemographic variables, awareness about 
the symptoms felt, patients' accessibility, screening versus diagnostic mammography, and 
potential barriers that may affect seeking health care.  
The second part is the system factors including presence of a standard protocol in patient's 
referral to imaging exams, imaging method of choice in the BC initial 
diagnosis,effectiveness, utilizedsector, costs and appointments, and follow up issue. 
The third one is the potential delay which can be attributed to patient, or system or both. In 
addition, between the three main parts, barriers to early diagnosis may be appearedas 
illustrated in (Figure 2.1).  
Symptoms 
BC Symptoms include a lump in breast or armpit, retracted nipple, nipple discharge, pain, 
tingling, one breast changes size or shape. Patients should be aware of specific cancer 
symptoms, understand the urgency of these symptoms, overcome fear or stigma associated 
with cancer and to be able accessing primary care. Thus, awareness has to be translated 
into appropriate health-seeking behavior. 
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Screening mammography  
BC can be detected in asymptomatic woman during her routine screening mammography. 
Diagnostic mammography  
BC can be discovered in woman after signs and symptoms have already appeared. 
Follow up cases after a previous breast problem 
The researcher also examines follow up of patients with previously reported problems in 
any breast imaging exam and the main causes of loss to follow up the patients. 
Accessibility 
Services are directly and permanently accessible with no unwarranted barriers of culture, 
language, or geography.  
The researcher considered three dimensions of accessibility: physical accessibility & 
affordability which reflect the availability of the service and referral, ability of a patient to 
pay for imaging diagnostic exams including the presence of health insurance, copayments, 
out of pockets payments and the transportation issue. The second one is the appointment & 
waiting time domain in order to perform the exam and to get the results.The third one is 
communication &patient respect within the service provided. 
 The researcher studied the overall accessibility for the performed diagnostic exams and if 
there are differences in patients' accessibility with regards to the sector they utilized. 
Potential delay 
Delay may occur during BC diagnosis. In the current study, the potential delay may be 
attributed to patient, or system, or both of them. 
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Patient delay 
Patient delay is the delay in seeking health care three months and moreafter patient noticea 
potential BC symptom. The researcher studied the main barriers facing the patients and 
prevents them to seek health care early. 
Diagnostic delay 
The current study focused on the delay in the final diagnosis three months and more after 
the patient counseled health care provider. Diagnostic delay was divided into five main 
stations to explore the most areas causing delay: referral delay, mammography delay, U/S 
delay, biopsy delay and histopathology delay. 
Barrier 
Perceived barrier is any obstacle face woman and prevent her to seek health care early. 
Patients were asked about barriers that may be related to health care system or to the 
patient in order to know the main barriers that actually affect the patients' early diagnosis.  
BC initial diagnosis 
The study assesses the presence of guidelines and protocol in referral of patients to BC 
diagnosis considering the imaging method of choice according to age. 
Referral 
According to the best practice guidelines, Patients with symptoms or signs of BC should be 
referred for assessment. The researcher studied to what extent physicians follow 
international guidelines when they refer suspected BC women to diagnosis.  
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Effectiveness and Efficiency 
Efficiency refers to doing things right whatever is performed; it is achieved in the most 
suitable way, given the available resources (high efficiency). 
 Effectiveness, on the other hand refers to doing the right things selecting and focusing on 
the goal achievement (BC diagnosis). 
In the current study, the researcher considers the imaging tool which correctly diagnose the 
case as effective modality and the imaging tool that is failed to diagnose the case as 
ineffectivemodality. 
 Concerning efficiency, the researcher adopted the American College of Radiology (ACR) 
guidelines regarding what should be done to diagnose suspected BC cases and if there 
waswastein the resources. 
Utilized Sector  
When patients seeking health care, they will choose one of the sectors provide BC 
diagnostic exams (mammography, U/Sand biopsy). These sectors are governmental 
hospitals, NGOs andthe private sector. 
Patient demographic data 
In this study, patient demographic data includes age at diagnosis, place of residence, level 
of education, socioeconomic status, and family history in order to assess the effect of these 
factors on patient delay and diagnostic delay. 
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Figure ‎2.1: Conceptual framework- Self constructed 
2.2 Breast cancer (BC) 
The breast is composed of three major structures: skin, subcutaneous tissue, and breast 
tissue (parenchyma and stroma). Parenchyma includes glandular tissues which housesmilk 
lobules and ducts, and stromal supporting tissues include fatty and fibrous connective 
tissues of the breast(Morris, 2005). 
American Cancer Society (ACS) defined BC as a malignant tumor that occurs as a result of 
uncontrolled cells growth in breast tissues. It can invade the surrounding breast tissues or 
spread to distant areas of the body. The evidence showed that BC occurs most frequently in 
women, but it can occur in men too (ACS, 2017a). 
18 
2.3 Breast cancer risk factors 
American Council on Science and Health(ACSH)stated that unlike other diseases, BC 
arises from the presence of multiple risk factors rather than one single cause. These factors 
can be divided into three main categories: The first category is the established risk factors 
including gender, age, benign breast disease, family history, early age at menarche, late age 
at menarche, late age at first full term pregnancy, obesity, physical inactivity and high dose 
of ionizing radiation exposure.  
The second category is the speculated risk factors including never have been pregnant or 
having one pregnancy, no breast feeding after pregnancy, postmenopausal hormonal 
therapy, high intake of fat, low intake of fibers, alcohol consumption, tobacco smoking, 
and abortion.  
The third category is the unsupported risk factors category including postmenopausal 
obesity, exposure to low dose ionizing radiation in midlife and high intake of 
phytoestrogen (ACSH, 2000) 
A master thesis study conducted at Al- Quds University aimed to examine the BC risk 
factors among females in GGs. The study showed that the major risk factors for BC are 
high socioeconomic status including high education level, increased household monthly 
income, and women employment (Hams, 2005). 
 The second risk factor was the family history. Also, the study showed increase BC among 
women with contraceptive use. An increased risk was also indicated among women with 
passive smoking, using hair dye, eating excessive meat and chicken, and drink excessive 
fruit juice. In addition, women with previous breast mass were at more risk to develop BC. 
The study also showed that breast feedingwas a protective factor against developing BC  
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Another master thesis study conducted at Al- Quds University, Gaza examined the 
association between environmental factors and BC. The study showed that there was a 
positive association between BC occurrence anda group of factors such as physical trauma 
in breast, past medication used for infertility as a chemical factor, types of oil used in 
cooking especially using margarine as a source of saturated fat, living beside the solid 
waste disposal sites, women who exposed during their work to pesticides, fertilizes and 
dusts, women dealing with crops by naked hands, and women who livingwith others 
working in a farm or in agricultural field (Ashour, 2011). The study was Consistent with 
Hams (2005) study regarding the positive relation between excess chicken and meat intake 
and risk of developing BC. 
2.4 Breast cancer types 
The most common types of BC are Invasive Ductal Carcinoma (IDC) and Invasive lobular 
Carcinoma(ILC) according to the site of its origin (ACS, 2015). Common types of BC 
include non- invasive BC and invasive BC .Non- invasive BC occur when malignant cells 
in the ducts do not invade the surrounding fatty and connective tissues.  
The most common type is the ductal carcinoma in situ (DCIS), and less frequently Lobular 
Carcinoma in Situ (LCIS). The other type of BC is the invasive BC in which the malignant 
cells invade the ducts into surrounding fatty and connective tissues.  
IDC begins in the milk ducts of the breast and penetrates the wall of the duct, and invades 
the fatty tissue of the breast and possibly other regions of the body. IDC is the most 
common type of invasive BC; accounting 80% of BC diagnoses. While, ILC begins in the 
milk lobules of the breast, but often spreads to other regions of the body. ILC accounts 
around 10% to 15% of BC(Sharma et al., 2010). 
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Less common types of BC are medullary carcinoma, colloid carcinoma, tubular carcinoma, 
inflammatory BC, Paget's disease and Phylloides tumor (ibid). 
2.5 Cancer Stage 
The most widely used method for staging cancer is TNM classification that developed by 
the International Union against Cancer. In which T is referred to clinical features of tumor, 
N is referred to regional lymph node and M is referred to the absence or presence of 
metastasis (Kufe et al., 2003). For more details see (Annex 3). 
2.6 Breast cancer burden 
2.6.1 Breast cancer global burden 
BC is the most common cancer among females in both developing and developed countries 
(Bener et al., 2008;Ibrahim et al., 2014;Baburinet al., 2016;Enayatrad et al., 2016).Itis 
becoming an increasingly urgent problem in low and middle income countries where 
incidence rate which was historically low have been increasing by as much as 5 % per year 
(Bray et al., 2013).In addition, Forouzanfar et al. (2011)revealed that there was a 3.1% 
annual increase in BC incidence, with an increase estimation of 641,000 cases in 1980 to 
1,643,000 cases in 2010.  
Moreover, a study estimated the incidence of cancer in European countries resulted in that 
BC is the most common cancer among European women and the third common cause of 
cancer deaths among them, with observed disparities among different countries (Ferlay et 
al., 2013). 
BC is the most common cause of cancer deaths worldwide with a responsibility ofmore 
than 522,000 deaths in 2012 (Ferlay et al., 2015). While it is the most frequent cause of 
cancer deaths in women in less developed regions (324,000 deathsand constituting14.3% 
of the total deaths), it is now the second cause of cancer deaths in more developed regions. 
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In addition, the range in mortality rates between world regions is less than that for 
incidence because of more survivability from BC in high-incidence developed regions 
(Torre et al., 2015) 
2.6.2 Breast cancer burden in Mediterranean region 
BC is the most frequently diagnosed female malignant disease in Arab populations, its 
incidence is lower in Arab countries than in Europe and USA, but it is rising fast 
(Chouchane et al., 2013).Also, El Saghir et al.(2007)had reported that almost half of the 
BC patients among Arab women are below 50 years and median age is 49–52 years while 
it is63 years in the industrialized nations.  
In addition, in the Gulf Cooperation Council states (United Arab Emirates, Bahrain, Saudi 
Arabia, Oman, Qatar, and Kuwait), it is reported that advanced BC is the most common 
causeof cancer affecting younger populations compared with other countries (Al-Othman 
et al., 2015). 
2.7 Diagnostic imaging modalities for breast cancer 
Several common imaging modalities used to diagnose BC, which have both advantages 
and limitations. 
2.7.1 Mammography 
 A technique for imaging breast tissues provides high-quality images at low radiation doses 
in the majority of patients (Nass et al., 2001).Mammography can be used in screening or 
diagnostic purposes.  
2.7.1.1 Screening Mammography 
A radiologic procedure applied to a woman who has no sign or symptom of a breast 
disease and is used for the early detection of BC (Joy et al., 2005). Annual screening 
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mammography of age-appropriate asymptomatic women is currently the only imaging 
modality that has been proven to significantly reduce BC mortality (Hellquist et al., 2011). 
In the GGs, there is no formal policy for screening mammography and no obvious 
guidelines neither for the health care providers nor to patients on the best time to do a 
screening mammography. However, currentlythere is a screening mammography program 
conducted by MOH for women over the age 40 years old. Also, a screening 
programfunded by UNRWA in contract with several NGOs and private sectors to conduct 
screening mammography for all suspected potential BC cases and all women over 35 years 
old with positive family history of BC (UNRWA, 2016).  
A studyconducted at Al- Quds University in order to evaluate the mammography services 
in GGsshowed that there were some barriers that hinder the Gaza's women to conduct a 
screening mammography including pain, discomfort, fear from mammography procedure 
and results, and the time consumed during the procedure (Jadallah, 2016). 
2.7.1.2 Diagnostic Mammography 
A diagnostic mammography is a radiologic procedure applied to a patient with signs and 
symptoms of breast disease, or a personal history of biopsy proven benign breast disease 
(Joy et al., 2005). The goal of mammography is the detection, characterization, and 
evaluation of findings suggestive of BC and other breast diseases.  
2.7.1.3 ACR guidelines for performance of diagnostic Mammography 
According to ACR, The indications to conduct mammography involve all the patients with 
symptoms of breast diseases including but not limited to palpable abnormality, persistent 
focal area of pain or tenderness, bloody or clear nipple discharge, and skin changes. Also, a 
finding appeared in screening mammography and need further investigation, a probably 
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benign radiographic finding that needs a short-interval follow up. In addition to 
contralateral breast follow up for patients previously diagnosed with BC (ACR, 2014). 
2.7.2 Ultrasound(U/S) 
U/S in breast imaging is primarily used to distinguish between cystic and solid massesthus 
this enhance its role in characterization of suspected malignant lesions (Hooley et al., 
2013). This is clinically important, as a simple breast cyst is a benign finding that does not 
require further work-up. Recent advances in U/S technology allow obvious improvement 
in characterizationof solid masses (ibid).U/S can be used as guidance in breast biopsy 
(Nass et al., 2001). 
2.7.2.1 ACR guidelines for performance of breast U/S 
 According to ACR, the appropriate indications for breast U/S include evaluation and 
characterization of palpable masses and other breast related symptoms. In addition, it can 
be used to evaluate suspected or apparent abnormalities detected on mammography. Also, 
it is used in the initial imaging evaluation of palpable breast masses in patients under 30 
years of age, in women with dense breast and in lactating and pregnant women. 
Furthermore, U/S can be used as guidance for biopsy and in the evaluation of patients in 
planning for radiation therapy, and as a complementary study to mammography in 
suggestive malignancy (ACR, 2016a). 
2.7.3 Biopsy 
High-quality breast imaging evaluation is necessary to detect early or subtle breast lesions 
as well as to accurately target these lesions for image-guided biopsy. Several imaging 
modalities are commonly available and in clinical use for image-guided breast 
interventions, including stereotactic guidance, ultrasound and MRI. The choice of guidance 
technique will depend on lesion visualization and accessibility, availability of the imaging 
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modality, efficiency, safety, patient comfort, and the practitioner’s experience(Bassett, et 
al., 1997). 
Breast biopsies should be performed under imaging guidance in order to guarantee 
accuracy and to decrease the number of repeated biopsies(Willett et al., 2010). The type of 
biopsy needles used for specific breast lesions and guidance methods vary around the 
world.  
There is a global trend toward progressively larger needles and more tissue samples per 
biopsy site have been noted(Ikeda and Miyake, 2016). Biopsy can be guided into several 
ways either by palpation during clinical examination, orU/Swhich has the advantage of 
safety and cost effectivenessthan other guidance modalities (Newell and Mahoney, 2014). 
Also, the literature showed that imaging guidance is more accurate than palpation in case 
of palpable breast mass (Hari et al., 2016).In addition, stereotactic guidance enables 
percutaneous placement of a needle within the breast to sample mammographically 
detected suspicious breast lesions(Rovera et al., 2008). 
2.7.3.1 Follow up after biopsy 
Post biopsy follow-up imaging, using the same imaging modality that guided the needle 
biopsy, should be done at 6, 12, 24, and perhaps 36 months post biopsy for all benign 
concordant lesions. Specific concordant lesions diagnosed as fibroadenoma or lymph node 
can have the initial follow-up at 12 months rather than 6 months. If the lesion increases in 
size at follow up imaging, the lesion should undergo repeated biopsy by needle or surgical 
excision biopsy (Ikeda and Miyake, 2016). 
 The literature shows that if there is discordance between imaging and pathology, 
histological evaluation is still needed. This can be accomplished either by repeat core 
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needle biopsy(CNB), perhaps with consideration of larger gauge or vacuum-assisted 
device, or surgical excision(Landercasperand Linebarger,2011; ACR, 2015). 
However, Somenonmalignant CNBfindings are considered “borderline” because of 
theirpotential association with malignancy. Such borderline lesions include atypical ductal 
hyperplasia, lobular neoplasia (atypical lobular hyperplasia or LCIS), papillary lesions, 
radial scars (complex sclerosing lesions), fibroepithelial lesions, columnar cell lesions 
(hyperplasia or flat epithelial atypia), spindle cell lesions, mucocele-like lesions, and 
pseudoangiomatous stromal hyperplasia. If CNB result with one of these histologic 
findings requires correlation with imaging and clinical findings to determine concordance, 
and to either exclude diagnosis of a malignancy by further histological evaluation or to 
establish a formal plan of follow-up through risk-based, shared decision-making with the 
patient (Johnson and Collins,2009;Neal et al., 2010;Landercasper and Linebarger,2011). 
2.7.4 Magnetic Resonance Imaging 
In MRI, a powerful magnet linked to a computer creates hundreds of detailed images of 
the organ in multiple sections without the use of ionizing radiation. Uses of MRI in breast 
imaging may include assessment of abnormalities that are unclear on a mammography, 
determination of the extent of tumor growth after initial diagnosis, and for evaluation of 
the effectiveness of treatments (Joy et al., 2005). 
2.7.4.1 ACR guidelines for performance of breast MRI 
MRI can be used to characterize and identify a lesion when mammography and U/S are 
inconclusive for the presence of BC. MRI can be used as guided biopsy, postoperative to 
detect BC recurrence. In addition, MRI is indicated in metastatic cancer with unknown 
origin and expected to be in breast with no mammography findings. Moreover, breast MRI 
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is indicated in case of suspicious cancer recurrence in women with history of BC when 
mammography and U/S are normal (ACR, 2013). 
2.8 Breast Imaging Reporting Data System(BI-RADS) 
 BI-RADS lexicon1 of the ACR has enabled more consistent assessment and management 
of nonpalpable breast imaging abnormalities. It offers a widely accepted risk assessment 
and quality assurance tool in mammography, U/S or MRI. Part of the initial 
implementation was to make the reporting of mammographymore standardized and 
comprehensible to the non-radiologists reading the report (ACR, 2013). 
In BI-RADS mammography are categorized from 0–6, with category 0 incomplete exam 
that requires further investigation and category 6 being biopsy proven malignancy. 
Categories 1 to 5 are further broken down into negative, benign finding, probably benign 
finding, suspicious and highly suggestive of malignant lesion respectively. 
 The advantages of BI-RADS classification system in reporting mammography and U/S 
had been previously studied well; it can be define an interpretation guide of the 
mammographic images, less related to the subjectivity of the radiologist. It also allows a 
homogenization of the radiological findings between the radiologists themselves, and 
between radiologists and clinicians. Thus, there are fewer misinterpretations of the reports 
(Lazarus et al., 2006;Kim et al., 2008) 
2.9 Breast cancer early diagnosis 
BC early diagnosis is the early identification of cancer in patients who have symptoms of 
the disease. So, the objective of early diagnosis is to identify the disease at the earliest 
possible stage and to link the patient to the diagnosis and treatment without delay. When 
done promptly, cancer may be detected at a potentially curable stage, improving survival 
and quality of life (WHO, 2017). 
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BC early diagnosis is different from screening in that screening seeks to identify pre-
clinical cancer in a healthy target population (ibid). There is an evidence that when the 
early diagnosis of cancer combined with accessible, affordable and effective treatment. 
The results are improvement in the stage of cancer at diagnosis and survivability as well 
(WHO, 2002). 
2.10 Components of BC early diagnosis 
WHO identified three main steps in BC early diagnosis and each step has its components 
and potential delay. The first step is patient awareness about BC symptoms and its 
potential delay is accessdelay. The second step is the clinical evaluation, diagnosis and 
staging and its potential delay is diagnostic delay. The third step is timely, accessible, 
affordable treatment and its potential delay is delay in access to treatment (WHO, 2017). 
2.11 Guidelines in the initial assessment of BC 
The best practice guidelines revealed that the patient with breast disease symptoms should 
undergo imaging test after taking history and doing clinical breast examination. According 
to her age, if the woman 40 years oldor more, she should do mammography first, then U/S 
in the initial assessment of breast disease. In contrast, the patient with less than 40 years 
old should start with U/S, then a mammography will be done for those who have 
suspicious of malignancy in the clinical or U/S findings (Willett et al., 2010). 
2.12 Referral of patients with suspected BC to imaging 
NCCP stated situations in which an urgent referral of patients with suspected BC should be 
occurred within 2 weeks. These situations include discrete breast or axillary lump 
(unilateral, distinct, separate mass in patients over 35 years), ulceration Skin distortion, 
nipple eczema, recent nipple retraction or distortion (less than 3 months), blood-stained 
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nipple discharge. Patients with an acute abscess should be referred immediately to the next 
available breast clinic.  
Furthermore ,NCCP suppose the early referral of patients within 6 weeks if the patients 
have one of the following:inflammationthat persists after antibiotics, persistently refilling 
or recurrent cystunilateral discharge (not blood-stained), intractable pain that does not 
respond to reassurance or to measures such as wearing a well-fitting bra, or a 3 month 
course of evening primrose oil or common analgesic drugs, discrete lump in women under 
35 years,asymmetrical nodularity that persists at review after menstruation (NCCP, 2012). 
2.13 Sensitivity of diagnostic imaging modalities in BC diagnosis 
After reviewing the literature, seemingly there is a debate about the sensitivity of imaging 
modalities used in BC diagnosis. In addition, there are several factors affecting these 
sensitivities.  
The evidence showed superior performance of U/S than that of mammography for the 
women under the age 40 years old (Osako et al., 2007;Loving et al., 2010;Appleton et al., 
2014). Besides that, several studies revealed that the sensitivity of mammography decrease 
with increase breast density.In their study Berg et al. (2004)showed that the sensitivity of 
mammography decreased from 100% in fatty breast to 45% in extremely dense breast. 
Consistent with this finding, in another study conducted with an aim to compare the 
effectiveness of mammography and MRI in assessment of multifocal and metacentric BC 
revealed that the sensitivity of mammography decrease with increased density from 80% of 
entirely fatty breast to 60% of dense one (Sardanelli et al., 2004).  
Moreover, the evidence showed that the tumor type also affects the sensitivity of imaging 
modalities for BC diagnosis. A statistically significant decrease in mammography 
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sensitivity according to cancer type was reported as the sensitivity decrease 81%, 55% and 
34% for IDC, DCISandILC respectively (Berg et al., 2004). 
Besides that, the literature revealed a highly diagnostic performance will be obtained by 
combining U/S together with mammography. In a cross sectional validation study, 45 
women with mean age of 45 ± 12.07 were included with complaint of breast mass.Based 
on histopathology report, 32 out of 45 patients were diagnosed to have BC, the sensitivity 
of U/S combined with mammography is 100% which is higher than that of mammography 
alone (90.6%) and this highlighted the benefit to combine these two modalities together 
(Fatima et al., 2015). 
About the importance of MRI in the assessment of residual tumors, a study assessed 39 BC 
patients who undergo chemotherapy. Dynamic contrast enhancement MRI showed a high 
correlation with postoperative histopathological findings which means that MRI is a valid 
technique in the assessment of residual tumors in this patients group (Zhou et al., 2016). 
2.14 Breast cancer missed during diagnostic imaging 
A study conducted in Egypt with an aim to investigate factors hindering early BC detection 
and in turn lowering mammographic sensitivity. The study included 152 
histopathologicalyproven breast carcinomas that were initially missed by mammography 
and were detected on double and re-reading by more experienced radiologists. Additional 
mammographic views were recommended in 35 (23%) cases. Complementary U/S 
examination was performed for all 152 cases (100%) and showed a higher sensitivity than 
mammography in carcinoma detection. This study concluded at four factors lead to miss 
carcinoma by mammography and these factors are patient's factors such as dense breast, 
tumor factors such as multicintric or multifocal tumors, technical factors such as exposure 
and provider factors such as bad interpretation (Kamal et al., 2007).  
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Also, Muttarak et al. (2006) study suggested that several factors causes carcinoma missed 
by mammography including dense breast parenchyma obscuring a lesion, perception error, 
interpretation error, unusual lesion characteristics, and poor technique or positioning. 
2.15 Diagnostic delay 
 In a qualitative study aimed to assess the diagnostic delay and its impact on stage of 
disease among women with BC in Libya, two hundred Libyan women aged 22–75 years 
with BC diagnosed during the years 2008–2009 were interviewed about their diagnosis of 
BC, the median diagnosis delay was 7.5 months, as 30% of patients were diagnosed within 
3 months after symptoms appeared, 14% were diagnosed within 3–6 months, and 56% 
within a period longer than 6 months. Diagnosis delay of >3 months was associated with 
bigger tumor size, positive lymph nodes, high incidence of late clinical stages, and 
metastatic disease (Ermiahet al., 2012).  
Results of diagnostic delay factors of bigger tumor size and positive lymph nodes were 
also revealed in another study (Redondo et al., 2009). 
2.15.1 Barriers affect early diagnosis of BC 
After reviewing the literature, it seems that there are multiple factors affecting the early 
diagnosis of BC and may affect the stage of cancer at the final diagnosis. These factors can 
be divided into two main components;Patient delay which is the delay in seeking medical 
consultation after self- discovering a potential BC symptom, and diagnostic delay which is 
the delay within the health care system in getting appointments, scheduling diagnostic 
tests, receiving a definitive diagnosis, and initiating therapy. 
 A study conducted at South African public hospital examined the effect of place of 
residence on the cancer stage in 1000 public sector patients, and revealed that62% of 
patients with a distance more than 20 km had a late stage of diagnosis if compared to 50 % 
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patients with less than 20 km. The study also revealed other factors contributing to delayed 
diagnosis may include lack of education, concerning where to go to seek help, poor 
knowledge of symptoms, lack of breast awareness, fear and beliefs hold on the causes of 
cancer and whether it is curable (Dickens et al., 2014). 
Low utilization of healthcare services by women with noncommunicable diseases in 
general has been documented (Ibanez-Gonzalez and Norris 2013). In addition, a qualitative 
study conducted with an objective to understand barriers to early diagnosis of symptomatic 
BC among black African, black Caribbean and white British women in the UK resulted in 
four types of barriers that may face women and hinder their early diagnosis. These barriers 
can be summarized as patient factors such as lack of awareness, difficulty appraising 
symptoms, fearing of cancers, and health care system barriers such as not knowing where 
to go, difficulties booking appointments, difficulty organizing and attending hospital 
appointments, and feeling disempowered (Jones et al., 2015).  
Also, Poum et al. (2014) studiedfactors associated with greater doctor delay (time from 
first consultation a health care provider to diagnosis of BC)in a multivariate analysis were 
previous breast symptoms, self-treatment, distance or travel time to hospital, younger age 
at first birth, and increased number of consultations with a surgeon before diagnosis. 
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Chapter3: Methodology 
This chapter provides comprehensive information of all aspects of research methodology. 
It explains the study design, study period and setting, study population, sample size and 
sampling process, toolsof data collection and analysis, reliability and validity of the 
instruments. In addition it clarifies the ethical considerations and studylimitations. 
3.1 Study design 
This study is designed as analytical retrospective cross sectionaldesign to assess the 
relationship between BC diagnosis by imaging modalities and other study parts; patient's 
factors, health care system factors and potential delay. The major purpose of cross 
sectional analytical method allows the investigator to use facts or information already 
available, and to analyze them to make a critical evaluation of the examined situation 
(Kothari, 2004;Levin, 2006). Retrospective study may be completed relatively quickly and 
cost-effectively, compared to other types of studies (Velengtas et al., 2012). 
The study is a triangulation study involving both quantitative and qualitative data using 
three main tools. The triangulation between the two methods creates inclusive information 
about the study domains that cannot be collected in one method. In addition, the 
combination between the two approaches maximizing the benefits of both and minimizing 
the limitations of each (Hussein, 2015). 
3.2 Study setting 
Quantitative data: The study was conducted in three main hospitals: 
 Daily care, outpatient's unit and archive of oncology department at Al-Rantesihospital. 
 Daily care, outpatient's unit and archive of oncology department at Gaza European 
hospital.  
 Computed Tomographydepartment at Al Shifa hospital. 
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Qualitative data:Data were collected at Al Shifahospital, Gaza European hospital, Al-
Rantisihospital, and PHC. 
3.3 Study population 
Quantitative and qualitative data of this study were collected through two populations.  
Quantitative part: women diagnosed with BC during the year 2017. The researcher 
selected this year for investigation becauseBC patientsare frequentlycome to the hospital in 
the first year of diagnosis. So, it is easier toreach them than patients diagnosed in any other 
year. In addition, to guarantee the presence of imaging reports before it may be lost and to 
minimize the recall bias resulted from the retrospective study design. 
Qualitative part:Doctors with various medical specialtieswho are involved in 
diagnosisBC patients. 
3.4 Eligibility criteria 
3.4.1 Inclusion criteria 
Quantitative part:Women diagnosed with BC during the year 2017 and registered at one 
of the oncology centers (Al-Rantesihospital or Gaza European hospital), and are under 
treatment and follow-up during the data collection period. 
Qualitative part:various medical specialistswho are involved in diagnosing BC patients 
(Radiologists, oncologists, histopathologists, surgeons and PHC (GPs). 
3.4.2 Exclusion criteria 
 Women who were newly diagnosed with BC as a secondary tumor for other primary 
sites. 
 Womanwho has a recurrence of BC after history of lumpectomy. 
 Unaware patients and those with mental disabilities were also excluded from the study.  
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3.5 Study period 
The study took 13 months to be conducted as it started in March 2017 and completed 
byMarch 2018. The research proposal has been defended in the front of school of public 
health assigned committee in May 2017. Initially, the research proposal described the entire 
process and provided information about study design, data collection and analysis methods 
and tools. After obtaining the committee's approval, the researcher prepared the required 
tools of this study. The tools were arbitrated by experts and their opinions were taken into 
considerations. The arbitration stage lasted for 6 weeks including reviewing of tools by the 
arbitrators and the academic supervisor’s feedback. In July2017 Arabic translation of the 
tool was finished with the help of the supervisor and a group of arbitrators. 
In August 2017 the tools were ready to start the data collection and the researcher trained 
one data collector and carried out the required training prior to piloting and field work. 
Piloting started between 20 and 28 August 2017. Actual data collection of quantitative part 
and data entry as well started on 10
th
Septemberthrough 5
th 
December 2017. The researcher 
and her assistant began collecting data in the outpatient's and daily care units during work 
days andhours. 
 Data entry was performed at the time of data collection. Analysis part of the study was 
immediately initiated after the completion of data collection. Data management and 
recoding of variables were done, descriptive analysis, frequency tables were extracted, and 
then inferential statistics were performed. In-depth interviews were done after analysis of 
quantitative part in January 2018. The researcher started to prepare the final report which 
has been finalized byMarch 2018. 
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3.6 Sample size and sampling process 
Quantitative part: The study included all women registered and under treatment and 
follow up in the two oncology departments (daily care and outclinic unit) during the data 
collection period. 
Previously, it was reported that cancer patients at North Gaza, Gaza city and Middle zone 
constitute 69.7%. In the other hand, cancerpatients atRafah and Khanyounis cities 
constitute 28.3% of the total number of cancer cases (MOH, 2015b). 
Oncology services at Gaza European hospital coversKhanyounis and Rafah areas while 
oncology services at Al-Rantesi hospital covers North Gaza, Gaza, and Middle area. Based 
on that, and with the help of the health staff members in the oncology departments in the 
two mentioned hospitals, questionnaires were distributed in the two oncology centers in the 
working days and hours of the two hospitals and the Table (3.1)below shows these 
distributions, inclusion and exclusion criteria were taken into consideration while 
distribution the questionnaires. Every patientwas asked about the date of diagnosis and if 
she was previously diagnosed with othertypes of tumors before starting filling the 
questionnaire. 
Table ‎3.1: Distributionquestionnaires byoncology centers 
Name of the hospital Distributed questionnaires (%) 
Al-Rantesi hospital 
70.7% 
Gaza European hospital 
30% 
Total 
100% 
Qualitative part: A purposive sample of thirteen different medical specialistsinvolved in 
BC diagnosis was selected. The integration between quantitative and qualitative data is 
important to deeply explore factors affecting early diagnosis issue and barriers that may 
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hinder this process. The qualitative component was carried out after finishing the 
quantitative one in order to deeply explore important issues emerged from the quantitative 
part.  
3.7 Study instruments 
Quantitative Part: The researcher developed two instruments (interviewed questionnaire 
and abstraction sheet). 
Interviewed questionnaire were fulfilled with BC women under treatment and follow up. 
The majority of questions were close-ended questions, and few of them were open-ended. 
See (Annex 4) and the translated version (Annex 5).  
These items were covered by the questionnaire:  
  Patients' sociodemographic data 
 Symptoms of the disease. 
 Number of consultations before diagnosis and referral. 
 History of previous examinations. 
 Questions about diagnostic process and what had been done  
 Delay time to seek health care. 
 Delay time to diagnosis. 
 Appointments for imaging examinations and questions about referral. 
 Patients' Accessibility, affordability for imaging diagnostic modalities  
 Perceived barriers (patient's facing barriers when seeking health care) 
 Patients' accessibility for the utilized imaging services measured on a 5-pointsLikert- 
scale ranging from 1 (strongly disagree) to 5 (strongly agree). 
The second instrument of the quantitative part is an abstraction sheet (Annex 6)which was 
developed to check patient's records about what had been done during diagnosis. The dates 
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of performing exams, report dates and conclusion of each exam were gathered. Sample 
(biopsy) dateand histopathology report date and result, tumor stage at the time of diagnosis 
were also collected. 
Qualitative Part: The researcher used open-endedquestions(semi-structured), see (Annex 
7) and the translated version (Annex 8). Questions were asked by the researcher within in-
depth interviews with thirteen different medical specialists working in BC diagnosis field. 
The interviews focusedon the diagnostic process and if there is available standard protocol 
in referral and diagnosis of BC, role of imaging tests in the diagnosis, patient delay in 
seeking health care and barriers that may affect early seeking health care, results of 
imaging tests and to what extent they are useful and effective in the diagnosis. 
3.8 Ethical and administrative considerations 
An ethical approval was asked for from School of Public Health at Al-Quds University and 
Helsinki Committee (Annex 9). Adminapproval was obtained from the human resource 
development general directorate in the MOHfor the three data collection tools (interviewed 
questionnaire, Review medical records, and in-depth interviews with medical specialists) 
see(Annex 10). To guarantee patient rights, a covering letter indicating that the 
participation is voluntary and confidentiality was assured for all of them. All patients were 
asked for their agreement to participate in the study (Annex 11). 
3.9 Pilot study 
Quantitative part: A pilot study included 12 BC cases (10 % of the total sample size) were 
done to explore the relevance of the study instruments and allow the research team to train 
for data collection; this step allowed exploring the appropriateness of the questions, 
patient's responsiveness and further improvement of the study validity and reliability. 
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Qualitative part: A pilot interview was done with a radiologist, which allowed for further 
improvement of the study validity and reliability. Based on the result of this stage; the 
questions were ordered and the way of asking the questions was improved to be more 
deeply. 
3.10 Data collection 
Quantitative part: After completing the pilot study, the researcher and one data collector 
gathered the data from the two-oncology centers according to working days and hours in 
the outpatient clinics and daily care of the two hospitals. Also, a number of women were 
interviewed at AlShifa hospital during their CT staging exam. The researcher herself filled 
the abstraction sheet by reviewing the medical files for all participants in the archive. In 
case of incomplete records, the researcher contacted with the patients in order to bring the 
required reports. This stage was completed after 3 months. Training was done for the data 
collector about the study aim and objectives and vague questions were clarified. In the 
field work, the researcher began to collect the data in order to help her assistant fully 
understand the questions and how to ask them. Confidentiality and privacy were taken into 
consideration. 
Qualitative part: Data were collected through thirteen in-depth interviews with different 
medical specialists(Annex 12) after the completion of the quantitative part.  
3.11 Response rate 
Quantitative data: During the time of data collection, 130 interviewed questionnaires 
were distributed in the two main oncology centers, of them 122 were fulfilled. So, the 
response rate was 93.8%.  
Qualitative data: Thirteenin-depth interviews were carried out and the response rate was 
100%. 
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3.12 Scientific rigor 
Quantitative part 
Validity 
 Face validity 
Interviewed questionnaire and abstraction sheet were organized in order to allow smooth 
data collection. 
 Content validity 
Concerning the content validity, adequate reviewing of related topics in the literature about 
BC early diagnosis by imaging tools and factors affecting it was done before designing the 
study instruments and tools. To assess the relevance of the questionnaire and abstraction 
sheet, experts conducted evaluation process(Annex 13), and comments were taken in 
consideration. In addition, the researcher reviewed some medical files prior to the study 
and check about the availability of study items. A validation data by identification number 
(ID) using excel sheet was used to avoid duplication of cases. In addition, a pilot study was 
conducted before the actual data collection to examine patient's responsesto the 
questionnaire and how they understand its questions. Slight modifications were done to 
make it well understood. This would increase the validity of the questionnaire. 
Reliability 
The following steps were done to assure instruments reliability: 
 Standardization of filling the questionnaires and abstraction sheets. 
 Data entry was done in the same day of data collection to permit possible interventions 
to assure data quality and to re-fill the questionnaire when it is required. 
40 
 Patients were contacted by the telephone to bring their reports in case of uncompleted 
medical files.  
 Re-entry of 5% of the data after finishing data entry was done to assure correct entry 
process and thus to decrease the errors. 
 Accessibility data were examined for internal consistency of its domains in order to 
ensure appropriateness of clustering statements. The researcher used Cronbach's alpha 
coefficient to check the reliability for each domain as illustrated in Table (3.2). 
Table ‎3.2:Cronbach's alpha coefficient for the main Domains 
Domain 
Alpha Coefficient 
No. of 
questions 
Mammography U/S Biopsy 
Physical accessibility & affordability 0.672 0.600 
 
0.69 
 
6 
Appointments &waiting time 0.710 
 
0.744 
 
 
0.741 
 
5 
Communication &patients right 0.610 
 
0.645 
 
 
0.612 
 
9 
 
Qualitative part  
To assure the trustworthiness of the qualitative part in this study, three steps were 
considered.First, a peer check was completed by health experts to review in-depth 
interview questions to assure that they cover all the essential domains. Second, points were 
taken about the important issues discussed during the interviews. Third, a debriefing report 
was written at the end of each interview including the most important points discussed 
during it. 
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3.13 Data entry and analysis 
 Quantitative part: The researcher used Statistical Package for Social Science (SPSS) 
program version 22 for data entry and analysis. The first stage of data entry was through 
constructing the entry base and coding of variables, followed by actual data entry. Data 
entry was performed at the time of data collection. At the analysis stage, data cleaning 
anddata management for the variables of interest were performed. 
 The management of data depended upon scientific literature, merging and discretizing 
continuous variables into categorieswith minimal loss of information.Descriptive analysis 
including figures, frequency tables, and cross tabulationwere used to describe the main 
features of the data. 
One way Analysis of variance (ANOVA)test was used to examine the relationship between 
patients' accessibility to diagnostic exams and sectorsthey utilized considering LSD post 
hoc to examine the differences within groups. Fisher's exact test was used in case of 
violated assumption in chi square.MacNemar test was used to examine the difference 
between U/S and mammography resultsin a dependent sample. 
 All these tests and others were used to analyze the quantitative data; Confidence interval 
was considered at 95% and p-value < 0.05 was considered statistically significant. 
Qualitative part: Open coding thematic analysis technique was used to analyze the 
transcripts of the in-depth interviews. The researcher would gain the main findings from 
the interviews. Then, categorization of related ideas, comparison and integration between 
the quantitative and the qualitative findings was done to create rich items for discussion 
and interpretation. Also, in-depth interviews were analyzed deeply to identify the most 
important factors affecting the diagnostic process. 
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3.14 Limitations of the study 
 The study included the patients registered in the oncology centers, while it did not 
include the unregistered patients. 
  Most of the time, medical records were not complete. This obliged the researcher to 
contact patients by the telephone in order to bring reports and this required too much 
time and efforts. 
 In some cases, the researcher could not gain full required data about the patient because 
of the incomplete medical records and patient's losing the reports or unwilling to 
bringthem. 
 And finally, frequent electricity cuts and limited access to international publications 
were also considered limitations for this study. 
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Chapter4: Results and discussion 
Introduction 
This chapter illustrates the main findings of the study and discusses them. Descriptive 
analysis of demographic characteristics of study participants was performed. Then 
participants were distributedby medical history, referral and diagnostic delaydata.The 
description interpretations were followed by inferential statistics to achieve the main 
objectives of the study. Also, qualitative findings were illustrated in a comparison with the 
quantitative findings. 
4.1 Descriptive analysis 
4.1.1 Distribution of the study participants by oncology center 
Data were collected from the two oncology centers in GGs, 73% of the 
studyparticipantsreceive their treatment and follow up at the oncology center inAl- Rantisi 
hospital and27% of the participantsreceive their treatment and follow up at the oncology 
center in Gaza European hospital as illustrated in Figure (4.1) below. 
 
Figure ‎4.1: Distribution of participants according to oncology centers 
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4.1.2 Demographic characteristics of study participants 
Regarding place of residence, patients were distributed along the GGs as the 
following:45.9% of the study participants are resident in the Gaza city. This result reflects 
the high population density of this city (PCBS, 2016a).Others are resident along other 
governorates: Middle zone area, North Gaza, Khanyounis, and Rafah constituting 19.7%, 
13.9, 12.3% and 8.2% respectively as shown in thefigure below(Figure 4.2). 
 
Figure ‎4.2: Distribution of BC patients according to place of residence. 
Results arein a line with a master thesis study conducted at Al- Quds University with an 
aim to examine determinants of 5- year survival for BC among Gaza's women.The result 
showed that the highest percentage of the study participants (53.4%)were resident in the 
Gaza city (Alagha, 2014). 
45 
Concerning age, the mean age of BC patients is 51.2 years old with a standard deviation 
(SD) 12. This finding compatible with Hassanein et al. (2017)finding that showed the 
mean age of BC among Saudi Arabian women was 51.9 years. 
Previously, Alagha(2014)showed that the mean age of women at the time of BC diagnosis 
in the GGs during the year 2007 was 53.4 years which is slightly higher than the current 
number.The researcher interprets the difference between the two studies in thatarecent 
progresswas achieved in mammography and U/S systems specialized for breast imaging in 
GGs.In addition, digital mammography systems with higher sensitivity to diagnose BC 
were adopted in MOH and some NGOs in the recent three years. Moreover, adoption of 
screening programs by the MOH and some international organizations help increase 
patient access to the diagnostic services and this may help in the early diagnosis of BC. 
Within in-depth interviews experts ensured our interpretation as one said:” The awareness 
programs executed by MOH and some organizations regarding BC and its symptoms and 
the presence of free of charge screening programs made a difference”. 
The majority of BC patients lie within the age groups (40-49) years, and (50-59) years 
constituting29.5% and 27.1% respectively, followed by the age group less than 40 years 
constituting 15.6%, the old age groups (60-69) years and (70 and more)years constituting 
around 18% and 9.8% respectively as illustrated inFigure (4.3). 
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Figure ‎4.3: Distribution of cases by age groups 
Findings are consistent with doctorate thesis conducted at Arab Emirates country which 
found that the most affected age group with BC was (41-50) years old (Elobaid, 2014). 
Besides thatAlghamdi et al. (2013)showed that the highest percentages (38.6% and 31.2%) 
of BC cases among Saudi Arabian women lie within the age groups (30–44) and (45–59) 
years respectively. In comparison, the result is inconsistent with the most affected age 
groups among American women(50-59), and (60-69) years old (ACS, 2015). This reflects 
the occurrence of BC among women in developing countries at earlier ages if compared to 
developed ones. Locally, Alagha(2014) study showed a consistent finding regarding the 
most affected age groups (40-49) and (50-59) constituting 22% and 32 % of study 
participants respectively. 
Other sociodemographic variables are illustrated in the Table (4.1): Marital status, number 
of children, level of education, occupational status, income andthe presence of health 
insurance. 
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Table ‎4.1: Summary of demographic characteristic of study participants 
Variable Categories Frequency (%) 
Marital status 
(n=122) 
Single 12 (9.8) 
Married 84 (68.9) 
divorced 3 (2.5) 
Widowed 23 (18.8) 
No. of children 
(n=122) 
No children 24 (19.7) 
1- 4 35 (28.7) 
5-7 34 (27.8) 
8 and more 29 (23.8) 
level of education 
(n=122) 
<secondary school 44(36.1) 
≥secondary school 78(63.9) 
Occupational status 
(n=122) 
No 98 (80.3) 
Yes 24 (19.7) 
Income 
( n= 115) 
>1000 NIS 59 (51.3) 
1000-2290 NIS 32 (27.8) 
≥ 2290 NIS 24 (20.9) 
Presence of health insurance 
(n=122) 
Yes 118 (96.7) 
No 4 (3.3) 
Regarding the marital status, the researcher noticed that the majority of the study 
participants are married, widowed, or divorced (90.2%), while few of them (9.8%) have 
not married before. This may be attributed to increasing the probability of BC occurrence 
with increasing age (ACS, 2015;McGuire et al.,2015) at the time women mostly will be 
married. This finding was in a linewith Alagha(2014)finding that showed a higher 
incidence of breastcancer among married (73.5%). On the other hand, this finding is 
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incompatible with other studies (Shamsi et al., 2013;Martínez et al., 2017)that showed a 
higher incidence of BC among participants that had not been married before in comparison 
with married women.  
Regarding the number of children, about 19.7% women had no children, 28.7% of them 
have 1-4 children. Furthermore, 27.8% of the study participants had 5-7 children and 
finally, 23.8% of them had 8 children and more.  
Concerning level of education, the author noticed that two thirds of study participants (63.9 
%) have finished at least secondary education. Contrary, 36.1 % of participants have less 
than secondary education. 
Regarding the occupational status, the majority of the respondents are unemployed 
(80.3%) and few (19.7%) have a work of different types including skilled, semiskilled, and 
unskilled workers. 
Regarding income, the study shows that more than half of the study participants 
(51.3%)have monthly income less than 1000 NIS. Unfortunately, 79.1 % of the study 
participants are living below the poverty line (2290 NIS)as it was previously determined 
(PCBS, 2016b).This mainly reflects the deteriorated economical Palestinians situation 
especially in the GGs as an impact of the israeli-imposed blockade and the several attacks 
on GGs in the recent years. 
About health insurance, the majority of the participants are health insured (96.7%) with 
various types of health insurance; compulsory, israeli workers, voluntary, Ministry of 
Social Affairs (MOSA) and old ages insurances.This reflects the universal coverage of 
health insurance in the GGs as it was stated before (WHO, 2016). 
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4.1.3 Medical history of study participants 
Table ‎4.2:Distribution of cases by medical history 
Variable Frequency (%) 
Presence of family history of BC 
Yes  41(33.6) 
No 81(66.4) 
Laterality 
Left side 67 (54.9) 
Right side 53 (43.5) 
Bilateral 2 (1.6) 
Presence of signs and symptoms 
Symptom Yes No 
Breast mass 99 (81.1) 23 (18.9) 
Pain 20 (16.4) 102 (83.6) 
Tingling 16 (13.1) 106 (86.9) 
Retracted nipple 16 (13.1) 106 (86.9) 
Unequal size of both breasts 9 (7.4) 113 (92.6) 
Tenderness 8 (6.6) 114 (93.4) 
Nipple discharge 7 (5.7) 115 (94.3) 
Mass under axilla 7 (5.7) 115 (94.3) 
 
Table (4.2)indicates that 33.6% of the study population hada family history of 
BC.Presence of afamily history amongparticipantsis related to sister, mother or Aunt. This 
percentage invites us to think deeply about the importance to target these women in the 
screening program. The literature showed that family history plays an important role in BC 
and is responsible for more than 20% of all BC among females (Collins et al., 2005; ACS, 
2015). 
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The current study shows that BC is more common in the left breast (54.9%) compared to 
the right breast (43.5%). Despite the compatibility of this finding with some studies in the 
literature (Fatima et al., 2015; Singh et al., 2016), it is not compatible with other (Afzal et 
al., 2009). The researcher interprets the inconsistency in these results by the differences in 
selection of samples with regards to other factors such as metastasis, and hormonal 
receptor status. 
"Receptors are proteins in cells that can attach to certain substances in the blood. Normal 
breast cells and some BC cells have receptors that attach to the estrogen and 
progesteronehormonesand depend on these hormones to grow"(ACS, 2017b). 
Moreover, the study shows that most of the study participants sought health care because 
of theappearance of one or more symptoms. Breast mass was noticed in 81.1% of study 
participants, painful breast among16.4%. Similarly, lump and pain are the major symptoms 
defined by women in Turkey (Ozmen et al., 2014). 
Other symptoms identified by the study participants include retracted nipples among 13.1 
%, and tingling among 13.1% of the respondents. Other symptoms includingunequal size 
of breasts, breast tenderness, nipple discharge and mass under axilla, all these symptoms 
constituting were noticed among few of the participants. 
4.1.4 Patients' perceived barriers to seek health care 
The study shows that only 21.3% of the study participants had not any barrier to seek 
health carewhenBC signs and symptoms appeared. A clear difference, 78.7% of study 
participants had one or more barriers to seek health care.Those barriers were divided into 
barriers related to patients including personnel, interpersonal and economic barriers and 
barriers related to the health system 
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4.1.4.1 Perceived barriers related to patients 
Table ‎4.3: Perceived barriers related to patients 
Variable Frequency (%) 
Personnel and interpersonal factors Yes No 
considering symptom was not serious 49 (40.2) 73 (59.8) 
feared of results 41 (33.6) 81 (66.4) 
No chief complaint 40 (32.8) 82 (67.2) 
Lack of pain 35 (28.7) 87 (71.3) 
Stigma 5 (4.1) 117 (95.9) 
I was not beable to organize my time 5 (4.1) 117 (95.9) 
Fear of pain related to the exams 5 (4.1) 117 (95.9) 
Shy to demonstrate symptoms to healthcare providers 5 (4.1) 117 (95.9) 
Lactation 4 (3.3) 118 (96.7) 
I went to traditional healers 4 (3.3) 118 (96.7) 
My husband prevented me 2 (1.6) 120 (98.4) 
Economic factors Yes No 
Cost of the exams 6 (4.9) 116 (95.1) 
Transportation costs 6 (4.9) 116 (95.1) 
 
Table (4.3) shows barriers related to patients and interpersonal factors, 40.2% of 
participants considered that the symptoms were not serious, 33.6% feared from the results, 
32.8 % said that there was no chief complaint,28.7% experienced painless symptoms. 
These barriers may delay seeking health care and thus delay the diagnosis and this will be 
examined later (4.2.2.2, page:77). 
The unawareness regarding these symptoms also appeared in the open-endedquestion 
about barriers as one of thewomen said "I felt the mass before 9 months and I did not care 
about. When the doctor told me that I should do mammography, I am really surprised that 
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it could be acancer….. Thanks God".After all, some specialists duringin-depth interviews 
attributed delay in seeking health care to social barriers rather than to unawareness as one 
of them said" Women became aware of BC symptoms as most of them have access to 
internet, social media. Patients usually delay seeking health care as they fear of social 
relationship especially husbands". Another expert said" Stigma and denial of having BC 
play a role in patient delay". 
Other barriers related to patient and interpersonal factors such as Stigma, inability to 
organize time, fear of pain related to the exams, shy to demonstrate symptoms to health 
care professionals, lactation, seeking traditional healers, prevention by husbands are all 
studied and were recognized among few of the study participants. 
Regarding the economic barriers, few patients experienced fear of the exam and 
transportation costs. This finding is attributed to universal coverage of health care, 
providing mammography service through free of charge screening programs.  
4.1.4.2 Perceived barriers related to the health care system 
Table ‎4.4: Perceived barriers related to the health care system   
Variable Frequency (%) 
Health care system barriers Yes No 
A previous examination with free results 12 (9.8) 110 (90.2) 
Didn’t know where to go 6 (4.9) 116 (95.1) 
A previous counseling visit and the doctor did not take care of the 
case 
5 (4.1) 117 (95.9) 
Complexity of referral system 4 (3.3) 118 (96.7) 
Place of diagnostic facility is too far 2 (1.6) 120 (98.4) 
Service is not available 1 (0.8) 121 (99.2) 
Lack of female health care providers 1 (0.8) 121 (99.2) 
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Regarding barriers related to thesystem, some of the study participants (9.8 %) recognized 
that a previous breast imaging anda negativeresult is a barrier to seek health care another 
time from their perspectives. Other barriers related to thesystem such as patient did not 
know where to go, a previous counseling visit and the doctor did not take care about the 
case, complexity of referral system, place of thediagnostic facility is too far, lack of female 
health care providers, unavailability of diagnostic services are all recognized in few of 
study participantsas shown in the Table (4.4).  
Conversely, in open-ended questions some patients recognized system barriers during their 
diagnosis, one of the females said "I went to the doctor from the first appearance of the 
lump, the doctor did not refer me to imaging and did not take care about me and said that 
I'm O.K…". 
4.1.5 Potential delay 
Table ‎4.5: Distribution of cases by potential delay categories 
Types of delay Categories Frequency (%) 
Total delay 
n =122 
≥ 3 months 51 (41.8) 
Patient delay 
n = 122 
≥ 3 months 24 (19.7) 
diagnostic delay 
n= 122 
≥ 3 months 15 (12.3) 
Referral delay 
n = 122 
<14days 8 (6.6 ) 
Mammography delay 
n=91 
<7days 10 (8.2) 
U/S delay 
n =111 
<7days 3 (2.7) 
Biopsy delay 
n = 112 
<14days 
 
29 (25.9) 
Histopathology delay 
n = 121 
<14days 56 (46.3) 
 
 
 
54 
Table (4.3) shows the distribution of study participants by potential delay categories, 
41.8% of patients have a total delay of 3 months and more which is considered a delay 
according to WHO report(WHO, 2017). 
19.7 % of patients were considered delayers in the time to seek health care (mean for all 
patients = 54.5 days).It is worth to mention here that there were 3 patients that did not seek 
health care for more than 3 years. Such cases were mentioned by different medical 
specialists within in-depth interviews for instancean oncologist said:" Unfortunately, we 
still see such cases. But, we cannot be certain about the exact time of developing cancer". 
On the other hand, 12.3% of patients experienced diagnostic delay of 3 months and more 
(mean for all patients= 35.8 days).  
In comparison, several studies reported patients' delay and diagnostic delay among breast 
cancer patients (Landolsi et al., 2010; Norsa'adah et al., 2011;Ghazali et al., 2013; Sharma 
et al., 2013; Ozmen et al., 2014; Poum et al., 2014). 
Regarding referral delay, 6.6 % reported a delay in referral more than 2 weeks and this is 
considered a delay according to international guidelines (NCCP, 2012). 
In brief, referral time is good in general but there is a need to take care about certain rare 
diseases that may be treated for a long time as other diseases rather than cancer such as 
Paget's diseases or inflammatory carcinoma. 
When a PHC doctor working at mammography screening program was asked about the 
referral, she excluded the occurrence of such situation and said "Doctors at PHC refer 
patients even though they did not have the actual sign and symptoms of BC, I do not expect 
referral delay to be occurred". 
Regarding to imaging delay,8.2 % of patients had reported a delay in performing 
mammography. Also, 2.7% of patients had reported a delay in conducting U/S. This delay 
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is occurredas a result of appointment to do the exam, or ignorance because of 
nonmalignant findings of the first imaging method. 
Furthermore, 25.9 % of patients reported a delay of more than 14 days in performing 
biopsy and 46.3% of them reported a delay of more than 14 days in getting the 
histopathology result. These delays differ with different sectors that will be discussed later. 
4.1.6 Patients'follow up after a previous breast problem 
Figure (4.4) indicates that the majority of the study participants (73.8%) have never been 
examined before, 18.8%had a previous breast exam in the purpose of diagnosis and few of 
them(8.2%) had a previous exam in the purpose of screening. 
 
Figure ‎4.4: Distribution of cases regarding the presence of a previous breast exam 
The result indicates underutilization of screening programs in the Gaza Strip that most of 
the cases undergo a mammography or any other breast exam when the signs of BC have 
already appeared. This result is in a line with the literature that showed underutilization of 
screening programs among women in GGs and Arab countries as well (Abu-Shammala and 
Abed, 2015;Donnelly et al.,2015). 
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The study shows that 9% of the participants lost follow up after benign findings in 
previous breast imaging done less than a year in the causes related to patients such as 
ignorance or causes related to the healthcare system. The proposed protocol for follow up 
of a probably benign lesionis a repetition of unilateral diagnostic mammography at 6 
months and a bilateral diagnostic mammography at 12 and 24 months, and optionally at 36 
months (Dorsi et al.,2003). Whereas, when mammography shows a definite benign mass 
(forexample lymph node, hamartoma,lipoma, calcified fibroadenoma, oil cyst) a clinical 
follow up is the appropriate management (ACR, 2016b). In brief, a previous negative result 
in either mammography or US does not mean mistake rather we should to enhance the 
follow up issue of these reported nonmalignant findings.  
In anopen-endedquestion, women explained this point as a barrier to early diagnosis as one 
womansaid:" When I did the previous exam before 9 months, the doctor said that I m O.K 
and did not say that I should come back for another test". The researcher comments at this 
point in that the success of follow up of benign lesions firstly need a specialist in order to 
follow up the case clinically, and secondly the patients should be invited by thespecialist 
after clarifying the negative consequences if the patient delayed.  
Different specialists within in-depth interviews mentioned that thefailure in the follow up 
process is considered a diagnostic delay, as one of theexpertsin the oncology field said 
"Absolutely, it is considered a delay in diagnosis, this woman should be at least 
programmedin a close follow up after benign findings in imaging or to be biopsied". 
4.1.7 Referral of suspected BC cases to diagnosis 
There is no clear process for the suspected BC cases to be referred for the diagnosis, and 
the process seems to be a complex and ambiguous one (scheme 4.1). 
About 49.2% of the study participants were referred firstly to surgeons for assessment, 
then to theimaging centers. In addition, UNRWA referred about 17 % of the total study 
57 
participants for imaging exams. PHC also referred 7.4% directly to imaging without 
surgery assessment.  
Other referrals to imaging centers,11.9% of the participantswere referred by emergency, 
cardiology,and thoracic surgery departments,or by a charitable society, or doctors with 
various medical specialists including endocrinologistandhistopathologist and others.  
 
Scheme ‎4.1: Referral of suspected breast cancer patients to imaging exams 
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Table ‎4.6: Referral of suspectedBCpatients to diagnosis 
Variable Categories Frequency (%) 
Number of counseling times 
before referral to imaging service 
1 time 49 (40.2) 
2-3 times 52 (42.6) 
≥ 4 times  19 (15.6) 
Did not counsel 2 (1.6) 
Utilized diagnostic modalities 
Mammography+ US+Biopsy 79 (64.8) 
U/S+ Biopsy 30 (24.6) 
mammography + Biopsy 12 (9.8) 
Only biopsy 1 (0.8) 
Ranking for utilized imaging 
modalities 
combined mammography & U/S- 
biopsy 
32 (26.3) 
Mammography- U/S – Biopsy 31 (25.4) 
U/S – biopsy 29 (23.8) 
U/S – mammography– biopsy 14 (11.5) 
Mammography– biopsy 10 (8.2) 
Biopsy- U/S 2 (1.6) 
U/S-Biopsy- mammography 2 (1.6) 
Biopsy 1 (0.8) 
U/S- Biopsy- combined 
mammography&U/S 
1 (0.8) 
 
Table (4.6)reveals 40.2% of the study participants were referred to imaging exams from 
the first counseling visit. 42.6% of the study participants counseled two or three times 
before referral to imaging diagnosis. In addition, 15.6 % of patients counseled 4 times 
andmore before starting imaging. Cancer signs and symptoms can be vague, non-specific 
or difficult to detect. In addition, general practitioners (GPs) in PHC and different 
specialists other than surgeons and oncologists see a limited number of cancer cases.  
59 
Health-care providers may lack physical exam skills or have insufficient time to assess 
suspicious cancer symptoms, such as inability to properly perform a clinical breast exam 
for a breast lump. These factors can lead to misdiagnosis and delayed detection. Within in-
depth interview a GP doctor identified the problem in assessing BC in the PHC said that" 
GPs have insufficient education and training courses about BC assessment". 
The study shows that suspected BC patients in GGs were referred to imaging examinations 
in different processes. For instance, around 26 % of the study participants conducted 
combined mammography and U/S (at the same time), then biopsy. Also, 25% of them 
conducted mammography, then U/S, and finally biopsy. Other diagnostic process, 23 % of 
participants conducted U/S, then biopsy. Moreover, 11.5 % underwent U/S, then 
mammography and finally biopsy. In addition, 8.2% of the participants conducted 
mammography then U/S.These inconsistent referrals to imaging exams did not follow 
international guidelines (Willett et al., 2010) as previously illustrated in chapter 2, ( p: 28-
29). 
The resultof the current study reflects the inactive standard protocol in assessment of 
suspected BC patients in GGs. This result wassupportedby open-ended question within in-
depth interviews and there is agreement among various specialists that there are no 
national guideline to diagnose BC, a consultant radiologist specialized in 
breastimagingfield said "There are no written guidelines about BC diagnosis, the only 
documented guidelines stated in 2010 particularly for mammography screening program 
at PHC and it is not generalized for all health institutions". Another expert said: "There is 
no generalized protocol for all the institutions; but we depend on European guidelines and 
some depends on American guidelines in the diagnosis process and follow up also". 
It is worth to mention here that there is no single case referred to conduct a breast MRI and 
that means MRI has no role in BC diagnosis in the Gaza Strip. The interviewed 
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radiologists agree with the result and one of them said "The role of MRI is only used when 
mammography and U/S are inconclusive, but we do not use it in the BC diagnosis because 
of disadvantages of MRI as it is expensive, does not be used in case of large breast and in 
calcified breasts but it has a role to differentiate between scar and recurrence of 
malignancy in case of lumpectomy". 
4.1.8 Distribution of cases by utilized sector 
Table‎4.7: Distribution of cases by examination performed and utilized sectors 
Variable Categories Frequency ( % ) 
Mammography No 30 (24.6) 
Yes 92 (75.4) 
If yes (n=92) 
Governmental hospital 31 (33.7) 
NGOs 55(59.8) 
Private 6 (6.5) 
U/S No 12 (9.8) 
Yes 110 (90.2) 
If yes (n=110) 
Governmental hospital 40 (36.4) 
NGOs 47 (42.7) 
Private 23(20.9) 
Biopsy 
 
No 0 (0.0) 
Yes 122(100) 
If yes (n=122) 
Governmental hospital 36 (29.5) 
NGOs 40 (32.8) 
Private 46 (37.7) 
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Variable Categories Frequency ( % ) 
Patients change the facility during the 
diagnostic process 
No 76 (62.3) 
Yes 46 (37.7) 
If yes (n= 46) 
Mammography 4 (8.7) 
U/S 3 (6.5) 
Biopsy 39 (84.8) 
Reasons for changingfacility 
n=46 
 
Appointment 19 (41.4) 
Availability 8 (17.4) 
Doctor advise 7 (15.3) 
Trust 6 (13.0) 
Affordability 3 (6.5) 
Health insurance 2 (4.3) 
Doctor refused to repeat 
biopsy 
1 (2.1) 
 
Regarding mammography, 33.7%of the referred tomammography conducted it at 
governmental hospitals and more than 59.8% conducted at NGOs, and only 6.5% at the 
private sector.It is noted that a high percentage of participants utilized NGOs and 
governmental hospitals for mammography service. This is related to low cost, or in 
sometimes costless mammography service at the two mentioned sectors unlike the private 
one. 
Regarding U/S, 36.4 % of participants utilized governmental hospitals, 42.7 % utilized 
NGOs and 20.9% utilized the private sector. 
Regarding biopsy, about 29.5% of the study participants conducted biopsy at governmental 
centers, and 32.8%of patients conducted it at NGOs and 37.7% of them conducted it at the 
private sectors as shown in theTable(4.7). 
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In the Gaza Strip, suspected BC patients are referred to mammography and U/S free of 
charge by UNRWA without covering the financial feesof biopsy. In addition, screening 
programs at NGOs cover only mammography and U/S and do not cover the financial cost 
of biopsy. This obliges the patient to change the facility for biopsy. In contrast, Cultural 
and Free Thought Association (CFTA) refer the patients to do the three exams at NGOs 
centers free of charge. Most of the time, patients conducted mammography and U/S at one 
facilityand changed the facility forthe biopsy because oflong appointment or unavailability 
of the service.  
4.1.9 Patients' accessibility to diagnostic services for breast cancer 
In order to analyze the patients' accessibility to diagnostic services for BC, the researcher 
arranged the statements into three main parts, accessibility &affordability domain, 
appointment&waiting time domain, and communication & patient's respect domain. 
Patientswere asked about the level of their accessibility regarding examinations that 
performed during the diagnostic process, Figure (4.5) shows the three accessibility 
domains and the percentage of their scores. 
 
Figure ‎4.5: Accessibility domains of patients according to diagnostic exams 
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The overall weighted mean for accessibility domains for mammography, U/S and biopsy 
are 82%, 80% and 78% respectively which reflect a high level of accessibility among study 
participants.For the three diagnostic exams, the researcher noted that the highest weighted 
mean scoreis for appointment& waiting time domain, followed byphysicalaccessibility & 
affordability, and the lowest mean score is for the communication& patients' respect 
domain that will be discussed for each method separately. 
4.1.9.1 Patients' accessibility to mammography service 
Table ‎4.8: Level of accessibility among study participants regarding mammography 
service, (n= 91) 
Variable 
Strongly 
disagree 
n 
(%) 
Disagree 
 
n 
(%) 
Not 
certain 
n 
(%) 
Agree 
 
n 
(%) 
Strongly 
Agree 
n 
(%) 
 
mean 
 
 
mean
% 
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b
il
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It was easy to reach 
to mammography 
center 
1(1.1) 4(4.4) 5 (5.5) 58 (63.7) 23(25.3) 4.08 81.5 
The distance 
between your place 
of residence and 
mammography 
center was suitable 
9 (9.9) 13 (14.3) 4 (4.4) 49 (53.8) 16 (17.6) 3.55 71 
Transportation is 
availableto 
mammography 
0 (0.0) 5(5.5) 2 (2.2) 54 (59.3) 30(33) 4.20 84 
In general, the 
performance of 
health care 
providers in 
mammographyis 
good 
2 (2.2) 4(4.4) 5 (5.5) 26 (28.6) 54 (59.3) 4.38 87.7 
The cost of 
mammography was 
reasonable 
7 (7.7) 6(6.6) 1 (1.1) 36 (39.8) 41 (45.1) 4.08 81.5 
The transportation 
cost to reach 
mammography 
center was suitable 
12(13.2) 13 (14.2) 5 (5.5) 33 (36.3) 28 (30.8) 3.57 71.4 
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The referral 
systemto 
mammography was 
within appropriate 
time 
3 (3.3) 2(2.2) 5 (5.5) 33 (36.3) 48 (52.7) 4.33 86.6 
The appointment to 
conductmammogra
phywas suitable for 
you 
3(3.3) 3(3.3) 2 (2.2) 35 (38.5) 48 (52.7) 4.34 86.8 
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Variable 
Strongly 
disagree 
n 
(%) 
Disagree 
 
n 
(%) 
Not 
certain 
n 
(%) 
Agree 
 
n 
(%) 
Strongly 
Agree 
n 
(%) 
 
mean 
 
 
mean
% 
Health care 
providers in 
mammography 
center committed 
with the 
appointments 
1(1.1) 1(1.1) 0 (0.0) 25 (27.5) 64 (70.3) 4.65 93 
Waiting time to get 
mammography 
service was 
appropriate 
3 (3.3) 9 (9.9) 1 (1.1) 42 (46.1) 36 (39.6) 4.09 81.8 
The result of 
mammography was 
received at 
anappropriate time 
1(1.1) 1(1.1) 0 (0.0) 39 (42.9) 50 (54.9) 4.49 89.9 
C
o
m
m
u
n
ic
a
ti
o
n
 a
n
d
 p
a
ti
en
t 
r
es
p
ec
t 
Health care 
provider at 
mammography 
centerintroduced 
him/ herself 
10(11) 36 (39.5) 14(15.4) 14 (15.4) 17 (18.7) 2.91 58.2 
Medical imaging 
procedure was 
explained by the 
health care provider 
in mammography 
8 (8.8) 13 (14.3) 3 (3.3) 42 (46.2) 25 (27.5) 3.69 73.8 
Health care 
provider answered 
your questions 
carefully in 
mammography 
3(3.3) 22 (24.4) 11 (12.2) 40 (44.4) 14 (15.6) 3.44 68.9 
Clean gownand 
coverlet were 
available in 
mammography 
1 (1.1) 2 (2.2) 2 (2.2) 40 (44) 46 (50.5) 4.41 88.1 
Privacy was valued 
during 
mammography 
0 (0.0) 1 (1.1) 0 (0.0) 23 (25.3) 67 (73.6) 4.71 94.3 
There was a female 
health careprovider 
in mammography 
1(1.1) 
 
0 (0.0) 0 (0.0) 24 (26.4) 66 (72.5) 4.69 93.8 
You were given 
enough time to 
explain your 
condition in 
mammography 
2 (2.2) 3 (3.3) 4 (4.4) 41 (45.1) 41 (45.1) 4.27 85.5 
No discrimination 
between patients in 
mammography 
5 (5.5) 3 (3.3) 2 (2.2) 45 (49.4) 36 (39.6) 4.14 82.9 
Feasible contact 
with mammography 
facility 
19 (20.9) 26 (28.6) 6 (6.6) 18 (19.8) 22 (24.2) 2.99 59.7 
Total 
Affordability and accessibility 4.0 80 
Waiting time and appointment 4.4 88 
Communication and patients respect 3.9 78 
Overall accessibility for mammography 4.1 82 
 
n: number of participants 
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Table (4.8) shows that the mean scores for accessibility domains –physical accessibility& 
affordability and appointment & waiting time for mammography services are 4.0 and 4.4 
(weighted mean 80% and 88%) respectively. These high scores of the two domains for 
mammographyservice reflect the presence of available and affordable service with good 
appointmentin general.  
Regarding communication& patient respect domain, the mean score is 3.9 (weighted 
mean= 78%). The researcher noted that the mean score for communication and patient 
respect is reduced by the patients'responses towards the statement" health care provider at 
mammographycenter introduced him/ herself".The weighted mean score is 58.2 % as more 
than 50 % of the study participants responded with disagree or strongly disagree. 
Health care team knows so much personal information about the patients, yet patients 
know nothing about them. Self-introduction of health care providers to patients is an issue 
of providing kind care. More consideration should be given to this point to increase the 
communication between health care providers and patients,and to make the patients more 
trust about the service provided.  
Regarding the statement "health care provider answered your questions carefully in 
mammography", it is noted that the weighted mean score is 68.9%, as 27.7% of the 
participants responded with disagree or strongly disagree.Patients usually wanted the 
mammography imaging specialist at the center to give the result immediately after 
conducting the examination, while writing mammography reports is the responsibility of 
the radiologist and not the technologist. In addition, radiologists do not be able to confirm 
the diagnosis by the results of mammography alone, and wait to completethe required 
investigations in order to confirm the diagnosis. Efforts should be done to write 
instructions about mammography and U/S technique and procedures. Also, the patients 
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should be informed that all the investigations complete each other and the patient should be 
wait to complete all of them to confirm the diagnosis. 
4.1.9.2 Patients' accessibility to U/Sservice 
Table ‎4.9: Level of accessibility among study participants regarding U/S service,  
(n= 110) 
Variable 
 
Strongly 
disagree 
n 
(%) 
disagree 
 
n 
(%) 
Not 
certain 
n 
(%) 
Agree 
 
n 
(%) 
Strongl
y agree 
n 
(%) 
mea
n 
mean
% 
A
ff
o
rd
a
b
il
it
y
 a
n
d
 a
cc
es
si
b
il
it
y
 
It was easy to reach 
to U/S center 
1 (0.9) 4 (3.7) 4 (3.7) 75(68.8) 25(22.9) 4.09 81.8 
The distance between 
your place of 
residence and U/S 
center was suitable 
11(10.1) 14 (12.8) 10 (9.2) 57(52.3) 17(15.6) 3.50 70.1 
Transportation was 
availableto the U/S 
1 (0.9) 4 (3.7) 3 (2.8) 69(63.2) 32(29.4) 4.17 83.3 
In general, the 
performance of 
health care 
providersin U/S was 
good 
1 (0.9) 7(6.4) 7 (6.4) 35(32.1) 59(54.2) 4.32 86.4 
The cost of U/S was 
reasonable 
10(9.2) 10(9.2) 4 (3.6) 3(33.0) 49(45.0) 3.95 79.1 
The transportation 
cost to reach U/S 
center was suitable 
11(10.1) 14 (12.9) 6 (5.5) 47(43.1) 31(28.4) 3.67 73.4 
W
a
it
in
g
 t
im
e 
a
n
d
 a
p
p
o
in
tm
en
t 
The referral systemto 
U/S was within 
appropriate time 
11(10.1) 14 (12.9) 6(5.5) 47(43.1) 31(28.4) 4.30 86.1 
The appointment to 
conduct U/S was 
suitable for you 
4(3.7) 4 (3.7) 3 (2.8) 40(36.6) 58(53.2) 4.32 86.4 
Health care providers 
in U/S center 
committed with the 
appointments 
1 (0.9) 2 (1.8) 0(0.0) 36(33.1) 70(64.2) 4.58 91.6 
Waiting time to get 
U/S service was 
appropriate 
5 (4.6) 8 (7.4) 2 (1.8) 54(49.5) 40(36.7) 4.06 81.3 
The resultof U/S was 
received at 
anappropriate time 
1 (0.9) 2 (1.8) 0 (0.0) 47(43.2) 59(54.1) 4.48 89.5 
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Variable 
 
Strongly 
disagree 
n 
(%) 
disagree 
 
n 
(%) 
Not 
certain 
n 
(%) 
Agree 
 
n 
(%) 
Strongl
y agree 
n 
(%) 
mea
n 
mean
% 
C
o
m
m
u
n
ic
a
ti
o
n
 a
n
d
 p
a
ti
en
ts
 r
es
p
ec
t 
Health care provider 
at U/S center 
introduced him/ 
herself 
17(15.6) 39(35.8) 12(11) 25(22.9) 16(14.7) 2.85 57.1 
Medical imaging 
procedure was 
explained by the 
health care provider 
in U/S 
9 (8.3) 15 (13.8) 7(6.4) 52(47.6) 26(23.9) 3.65 73.0 
Health care provider 
answered your 
questions carefully in 
U/S 
1(0.9) 27 (24.8) 12 (11) 50(45.9) 19(17.4) 3.54 70.8 
Clean gownand 
coverlet were 
available in U/S 
0 (0.0) 0(0.0) 4 (3.7) 53(48.6) 52(47.7) 4.44 88.8 
Privacy was valued 
during U/S 
0 (0.0) 1 (0.9) 0 (0.0) 38(34.9) 70(64.2) 4.62 92.5 
There wasa female 
health careprovider 
in U/S 
36 (33) 15 (13.7) 4 (3.7) 27(24.8) 27(24.8) 2.94 58.9 
You were given 
enough time to 
explain your 
condition in U/S 
0 (0.0) 6 (5.5) 4 (3.7) 57(52.3) 42(38.5) 4.24 84.8 
No discrimination 
between patients in 
U/S 
5 (4.6) 4 (3.7) 2 (1.8) 56(51.4) 42(38.5) 4.16 83.1 
Feasible contact with 
U/S facility 
21(19.3) 35 (32.1) 5 (4.6) 24 (22) 24 (22) 2.95 59.1 
Total 
Affordability and accessibility 3.9 79 
Waiting time and appointment 4.3 87 
Communication and patients respect 3.7 74 
Overall accessibility for U/S 
4 80 
 
n: number of participants 
Table (4.9) shows that the mean scores for accessibility to U/S service; physical 
accessibility &affordability, appointment &waiting time are 3.9, and 4.3 (weighted 
mean=79% and 87%)respectively. These high scores reflect the high physical accessibility 
and affordability within appropriate appointments.The mean score for communication& 
patient's respect domain is 3.7 (weighted mean=74%).The researcher noted that the domain 
scorewas reduced by the responses towards the statement" health care provider at U/S 
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center introduced him/ herself" with a weighted mean score 57.1% as 51.4%of the 
participants responded with disagree or strongly disagree. 
The other statement reduced the domain score is "there was a female health care provider 
in U/S" with a weighted mean score 58.9% as 46.7% of the participants responded with 
disagree or strongly disagree. The researcher comment about this point in that breast 
imaging includes sensitive procedures that may be socially unaccepted. Therefore, we have 
to focusat this point and to develop femalehealth care providers in all types of breast 
imaging including radiologists, technologists and nurses to make breast imaging field more 
acceptable to women and thus more accessible. 
Finally, the score also was reduced by the responses towards the statement" feasible 
contact with U/S facility" with a weighted mean score 59.1% as 51.4% of the study 
participants responded with disagree or strongly disagree.The contact between patients and 
medical facilities is important for the patients and health care providers as well as it help in 
appointment process and inquire about the case especially when the case scheduled within 
a follow up program. 
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4.1.9.3 Patients' accessibility to biopsy service 
Table ‎4.10: Level of accessibility among study participants regarding biopsy service, 
(n= 121) 
Variable 
 
Strongly 
disagree 
n 
(%) 
disagree 
 
n 
(%) 
Not 
certain 
n 
(%) 
Agree 
 
n 
(%) 
Strongly 
agree 
n 
(%) 
mean 
 
mean
% 
P
h
y
si
ca
l 
a
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b
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y
a
n
d
 a
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o
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a
b
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It was easy to reach to 
the biopsy center 
1 (0.8) 6 (5) 6 (5) 78(64.4) 30 (24.8) 4.07 81.4 
The distance between 
your place of residence 
and biopsy center was 
suitable 
12 (9.9) 21 (17.4) 8 (6.6) 62(51.2) 18 (14.9) 3.44 68.8 
Transportation was 
availableto biopsy 
1 (0.8) 7 (5.8) 2 (1.7) 73(60.3) 38 (31.4) 4.16 83.2 
In general, the 
performance of health 
care providers in 
biopsywas good 
2 (1.7) 6 (5) 6 (5) 37(30.5) 70 (57.8) 4.38 87.6 
cost of biopsy was 
reasonable 
30(24.8) 15 (12.4) 2 (1.7) 39(32.2) 35 (28.9) 3.28 65.6 
The transportation cost 
to reach biopsy 
centerwas suitable 
15 (12.4) 18 (14.9) 6 (5) 47(38.8) 35 (28.9) 3.57 71.4 
W
a
it
in
g
 t
im
e 
a
n
d
 a
p
p
o
in
tm
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t 
The referral systemto 
biopsy was within 
appropriate time 
3 (2.4) 4 (3.3) 6 (5) 45(37.2) 63 (52.1) 4.33 86.6 
The appointment to 
conduct biopsy was 
suitable for you 
4 (3.3) 5 (4.1) 2 (1.7) 43(35.5) 67 (55.4) 4.36 87.2 
Health care providers 
in biopsy center 
committed with the 
appointments 
1 (0.8) 1 (0.8) 0 (0.0) 39(32.2) 80 (66.2) 4.62 92.4 
Waiting time to get 
biopsy service was 
appropriate 
5 (4.1) 11 (9.1) 3 (2.5) 48(39.7) 54 (44.6) 4.12 82.4 
The result of 
histopathology was 
received at 
anappropriate time 
13 (10.7) 15 (12.4) 2 (1.7) 43(35.5) 48 (39.7) 3.81 76.2 
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Variable 
 
Strongly 
disagree 
n 
(%) 
disagree 
 
n 
(%) 
Not 
certain 
n 
(%) 
Agree 
 
n 
(%) 
Strongly 
agree 
n 
(%) 
mean 
 
mean
% 
C
o
m
m
u
n
ic
a
ti
o
n
 a
n
d
 p
a
ti
en
ts
 r
es
p
ec
t 
Health care provider at 
biopsy center 
introducedhim/ herself 
15 (12.5) 39 (32.2) 12 (9.9) 27(22.3) 28 (23.1) 3.12 62.4 
Medical imaging 
procedure was 
explained by the health 
care provider in biopsy 
6 (5) 14 (11.5) 4 (3.3) 55(45.5) 42 (34.7) 3.93 78.6 
Health care provider 
answered your 
questions carefully in 
biopsy 
2 (1.7) 22 (18.3) 9 (7.5) 56(46.7) 31 (25.8) 3.77 75.4 
Clean gownand 
coverlet were available 
in biopsy 
0 (0.0) 0 (0.0) 3 (2.5) 54 (45) 63 (52.5) 4.50 90 
Privacy was valued 
during biopsy 
1 (0.8) 1 (0.8) 0 (0.0) 41(34.5) 76 (63.9) 4.60 92 
There was a female 
health careproviders in 
biopsy 
50 (42) 21 (17.6) 5 (4.2) 29(24.4) 14 (11.8) 2.46 49.2 
You were given 
enough time to explain 
your condition in 
biopsy 
1 (0.8) 4 (3.3) 6 (5) 57(47.6) 52 (43.3) 4.29 85.8 
No discrimination 
between patients in 
biopsy 
5 (4.1) 3 (2.5) 3 (2.5) 60(49.6) 50 (41.3) 4.21 84.2 
Feasible contact with 
biopsy facility 
17 (14) 36 (29.8) 8 (6.6) 26(21.5) 34 (28.1) 4.07 81.4 
Total 
Affordability and accessibility 3.8 76 
Waiting time and appointment 4.2 84 
Communication and patients respect 3.8 76 
Overall accessibility for biopsy 3.9 78 
 
n: number of participants 
Table(4.10) shows that the mean score for physical accessibility &affordability 3.8 
(weighted mean score=76%). The researcher noted that the domain score is reduced by the 
respondedtowards the statement" the distance between your place of residenceand biopsy 
center was suitable" with a weighted mean score 68.8% as 27.3% of the study participants 
responded with disagree or strongly disagree. The author comments about this result in that 
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not all the imaging centers have the possibility to do biopsy,andthisobliges the patient to 
change the facility in order to complete the diagnostic process. As far as the researcher 
concerned, completion of the diagnostic process in one facility and within few visits is an 
important issue for the patient in order to reduce financial and psychological burden as 
well. 
Also, the domain score is affected by therespondedtowards the statement" cost of biopsy is 
reasonable" with a weighted mean score 65.6% as 37.2% of the study participants 
responded with disagree or strongly disagree. The researcher interpretsthis finding in that 
screening programs at NGOs and UNRWA do not cover biopsy fees. Therefore, patients 
performed biopsy out of pocket (Range, 200- 800 NIS) and this is considered too much 
from their perspectives. 
The mean score for appointment & waiting time for biopsy service is 4.2 (weighted mean 
score is 84%). The researcher noted that patientshave very good responses for all 
statements except for the statement"the result of histopathology was received at an 
appropriate time" with a weighted mean score of 76.2%as 23.1% of the study participants 
answered with disagree or strongly disagree. After biopsy, the sample should be exist in 
the histopathology department for several days in order to interpret it by histopathologist. 
It is worthy to mention here that patients perform biopsy at the governmental hospitals 
have two types of delay, an appointment to perform the biopsy and another delay to get the 
histopathology result. In contrast, Samples at NGOs or private sector are examined at a 
shorter delay time if compared to governmental hospitals. Within in-depth interview, 
histopathologists attributed the delay in governmental hospitals to many factors as one of 
them said" The maximum time for histopathology report to be ready is 11 days, there are 
cases finished before that time, this depends on the tumor nature as sometimes 
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requiresmuch effort and time to decide about it, a device stop working, unavailable 
materials, weekends, and holidays, all these factors may cause delay in report delivery". 
Regarding communication and patient respect domain, the mean score for this domain is 
3.8 (weighted mean score =76%). The score of this domain was affected by the 
responsestowards the statement"health care provider at biopsy center introduced him or 
herself" with a weighted mean score 62.4% as 44.7% of the study participants 
respondedwith disagree or strongly disagree. Also, the domain is affected by the responses 
towards the statement"there was a female health careprovider in biopsy center" with a 
weighted mean score 49.2% as 59.6% of the participants'respondedwith disagree or 
strongly disagree. 
4.1.10 Patient's medical records 
Table ‎4.11: Documentation in the patients’ medical records 
Variable Categories Frequency (%) 
Mammography records 
n=92 
Report was not found 39 (42.4) 
Report wasfound 53 (57.6) 
U/S records 
n=110 
Report wasnot found 41 (37.3) 
Report wasfound 69 (62.7) 
Biopsy records 
n=122 
Report wasnot found 2 (1.8) 
Report wasfound 120 (98.2) 
Cancer stage as documented 
I 1 (0.8) 
II 13 (10.7) 
III 28 (23) 
IV 13 (10.7) 
Not reported 65 (53.3) 
file was not found 2 (1.5) 
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The researcher found that there is incompleteness in the patient's medical recordsas 42.4% 
of mammography reports and 37.3% of U/S reports are not found in the patients' file. 
Regarding histopathology reports, the researcher found that most reports are found in the 
patients' file (Table 4.11). 
Oncologistswereasked about this issue and assured that the presence of mammography and 
U/S reports in the medical file is crucial, one of them said "we depend on mammography 
and U/S in the management process and it should be exist in the patient file. But, maybe 
there is a problem regarding follow up of records and what is important to be kept".  
Regarding stage of cancer, only 11.5% of participants were reported as either stage I or 
stage II. This is due to delay in the diagnosis for the factors related to patients or system. 
About 33.7% were reported as stage III or IV. Unfortunately, more than half of the study 
participants (53.3%) were not reported to any stage at the time of data collection. Within 
in-depthinterviews oncologists confirmed its importance and one of them said"it is 
mandatory to document the patient stage as the management plan depends on what stage 
the patient is". 
4.2 Inferential analysis 
4.2.1 International guidelines for referral to imaging diagnostic methods(effeciency) 
The researcher interested to know if physicians in GGs follow the international guidelines 
whenthey choose the firstmethod to diagnose BC according to age(Willett et al., 2010). 
 
 
 
Table ‎4.12: Method of choice in imaging related to age categories 
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Age categories Method of first choice Frequency (%) 
>40 years 
n= 24 
Mammographyfirst 2 (8.3) 
U/S first 18 (75) 
biopsy first 1 (4.2) 
Combined mammography with U/S 3 (12.5) 
≤40 years 
n= 98 
Mammographyfirst 39 (39.8) 
U/S first 28 (28.6) 
biopsy first 2 (2) 
Combined mammography with U/S 29 (29.6) 
 
Table (4.12)clarifies the distribution of cases the first method selectedin BC initial 
diagnosis. For patients in the age group less than 40 years,75%of study participants 
performed U/Sfirst, 8.3% performed mammography first and 4.2% performed biopsy first. 
On the other hand, 39.8% of participants in the age 40 years or more performed 
mammography first, 28.6 %performedU/Sfirst and 2% performed biopsy first. Considering 
guidelines in the initial diagnosis of BC, there were12.5% of patients in the age group less 
than 40 years started their diagnosis by either mammography or biopsy which did not 
follow standards and is considered inefficient process.  
Also, 30.6% of participants in the age group 40 years and more started their diagnosis with 
either U/S or biopsy which did not follow standards and also is considered inefficient 
process. The differences in the choice of imaging method reflect that the present guidelines 
for BC assessmentare not generalized for all institutions. This finding is consistent with in-
depth interviews findings as one of the expert said" There is no guideline about what 
should be done. The choice basedon physician experience and what hesees". 
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4.2.2 Relationship between patient delay to seek health care and other factors 
4.2.2.1 Relationship between patients delayand demographic variables 
Table ‎4.13: Relationship between patients delay and some demographic variables 
p-
value 
2 
Patient's delay 
Categories Variable Delayers 
≥3months 
Non delayers 
<3 months 
0.46 
0.17 
4 (16.7) 20 (20.4) 
< 40 
Age 
20 (83.3) 78 (79.6) 
≥ 40 
0.67 2.35 
4 (16.7) 13 (13.3) North Gaza 
Place of residence 
13 (54.1) 43 (43.8) Gaza 
4 (16.7) 20 (20.4) Middle zone 
1 (4.2) 14 (14.3) Khanyounis 
2 (8.3) 8 (8.2) Rafah 
0.85 0.32 
13 (54.2) 46 (50.5) 
< 1000 NIS 
Income 
7 (29.2) 25 (27.5) 
1000- 2290 NIS 
4 (16.7) 20 (22.0) 
≥ 2290 NIS 
0.52 0.407 
10 (41.7) 34 (34.7) 
< secondary school 
level of education 
14 (58.3) 64 (65.3) 
≥ secondary school 
0.65 .203 
15 (62.5) 66 (67.3) no 
Family history of BC 
9 (37.5) 32 (32.7) yes 
 
Table (4.13) shows that there is no statistically significantrelationshipbetween patient 
delay and examined demographic variables (Age, place of residence, income, level of 
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education, and family history of BC). By comparison, the literature showed a significant 
effect of sociodemographic factors on patient delay in seeking health care after 
theappearance of BC symptoms (Khan et al., 2015;Ozmen et al., 2014;Ermiahet al., 
2012).Another study, Altwalbeh et al.(2015)showed that the only sociodemographic factor 
affecting patient's delay was age. The inconsistency of results could be interpreted by the 
differences in the patient's context about the social norms, communities,and 
encouragement by the family members. Also, in the GGs, health insurance coverage and 
the presence of free of charge mammography provided by more than one provider could 
enhance the accessibility of the service for all. 
4.2.2.2 Relationship between patient delay and perceived barriers 
Table ‎4.14: Relationship between patient delay and perceived barriers 
CI O.R 
p-
value 
2 
 
Patients' delay 
Variable 
 
Delayers 
≥3 months 
Non 
delayers 
<3 months 
(3.5-29.7) 10.2 0.00* 22.67 
21 (80.8) 28 (29.2) Yes 
Considering 
symptom was not 
serious 5 (19.2) 68 (70.8) No 
(1.6-9.5) 3.11 0.003* 9.3 
15 (57.7) 25 (26.0) Yes 
No chief complaint 
11 (42.3) 71 (74.0) No 
(1.7-10.3) 4.2 .001* 10.2 
14 (53.8) 21 (21.9) Yes 
Lack of pain 
12 (46.2) 75 (78.1) No 
(0.43-2.64) 1.1 0.902 .015 
9 (34.6) 32 (33.3) Yes 
Feared of results 
17 (65.4) 64 (66.7) No 
 
*statistically significant, 

Fisher's exact test 
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Table (4.14) shows that there are some barriers related to patientsthat affect the time to 
seek health care afterappearance of BCsymptom. The researcher found these barriers are 
the most recognized barriers among patients. The relationship between such barriers and 
patient delay was examined by performing Chi square test.Regarding the barrier" 
considering symptom was not serious", chi square testrevealed that patient who had 
experienced this barrier was more likely to be delayed than those had not (2 =22.6, p-
value= 0.00).Also, the study revealed that patient who hadexperienced such barrier was 
exposed to delay in seeking health care 10 times more than that who had not (O.R= 10.2). 
The result is supported by the result of Ozmen et al.(2014) study.  
Regarding the barrier" no chief complaint", the study showed that patient experienced such 
barrier was more likely to be delayed than thathad not (2=9.3, p-value= 0.003). Also, the 
study revealed that patientwho had experienced this barrier was exposed three times to 
delay more than that who had not (O.R= 3.11). 
Regarding to the barrier "experiencing painless symptom", the study showed that patient 
experienced such barrier was more likely to be delayed than that had not (2=10.2, p-
value= 0.001). Also, the study revealed that patient who had experienced this barrier was 
exposed four times to delay more than those had not (O.R= 4.2). 
All these results reflect lack of awareness among women in GGs regarding signs and 
symptoms of BC and there is a necessity to educate them in order to seek health care 
earlier.  
Regarding barrier "feared of results", the study showed that there is no association between 
patient experienced fear of results and the time to seek health care (2= 0.015, p-value 
=0.9). 
Inconsistent findings appeared within in-depth interviews regarding patients’ delay in 
seeking health care that it is attributed to other barriers rather than awareness and education 
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as one oncologist said "Social barriers and fear from husband abandon is very important 
in our society. Although educated women are aware of BC and its symptoms, they mostly 
come in anadvanced stages of the disease". 
4.2.3 Relationship between diagnostic delay and other factors 
4.2.3.1 Relationship between diagnosticdelay and demographic variables 
Table ‎4.15: Relationship between diagnosticdelay and demographic variables 
p-value 
2 
 
Diagnostic delay 
Categories Variable Delayers 
≥3 months 
Non-delayers 
<3 months 
0.045* 4.47 
6 (40.0) 18 (16.8) < 40 
Age 
9 (60.0) 89 (83.2) ≥ 40 
0.915 0.96 
2 (13.2) 15 (14.0) North Gaza 
Place of Residence 
7 (46.7) 49 (45.8) Gaza 
4 (26.7) 20 (18.7) Middle zone 
1 (6.7) 14 (13.1) Khanyounis 
1 (6.7) 9 (8.4) Rafah 
.063

 5.512 
10 (83.4) 49 (47.6) <1000 NIS 
Income 1 (8.3) 31 (30.1) 1000-2290 NIS 
1 (8.3) 23 (22.3) ≥ 2290 NIS 
0.08

 3.83 
2 (13.3) 42 (39.3) < secondary 
school 
level of education 
13 (86.7) 65 (60.7) ≥ secondary 
school 
0.39 0.313 
9 (60.0) 72 (67.3) No 
Family history of BC 
6 (40.0) 35 (32.7) yes 
 
*statistically significant, 

Fisher's exact test 
79 
To examine the relationship between diagnostic delay and patient's age, chi square test was 
performed. The testrevealedthat patients aging less than 40 years old experienced 
diagnostic delay more than those aging 40 years and more (2= 4.47, p-value=0.045).The 
researcher interprets this result in that it is known among health care providers that BC in 
young ages is uncommon so older patients are prioritized by physicians and receive a faster 
diagnostic process.Also, younger patients may utilize the service immediately after feeling 
symptoms of the disease in comparison with old ages. In addition, mammography 
sensitivity increase with increasing age as the breast density decreases. These results are 
agree to some extent to the literature (Ozmen et al., 2014;Ermiahet al., 2012).For the other 
examined demographic variables, chi square testrevealed that there are no statistically 
significant differences in diagnosticdelay and the examined sociodemographic variables 
(place of residence, income, education level, and the presence of family history of BC) as 
indicated in the Table (4.15). 
4.2.3.2 Relationship between diagnosticdelay and imaging findings 
Table ‎4.16:Relationship between diagnosticdelay and imaging findings 
CI O.R 
p-
value 
2 
Diagnostic delay 
Categories Variable 
Delayers 
≥3 months 
Non 
delayers 
<3 months 
(2.3- 30.1) 8.4 0.001
*
 14.4 
3 (33.3) 68 (86.1) 
malignant 
findings Mammography 
findings 
6 (66.7) 11 (13.9) 
Nonmalignant 
findings 
(1.4- 9.5) 3.73 0.018
*
 7.4 
9 (64.3) 85 (90.4) 
malignant 
findings U/S  
Findings 
5 (35.7) 9 (9.6) 
Nonmalignant 
findings 
 
*statistically significant, Fisher's exact test 
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The researcher wanted to know if nonmalignant finding in either mammography or 
U/Sincrease the chances ofdiagnosticdelay. For this purpose, the researcher performed chi 
square test.The reading of Fisher's exact test revealedthat there is a statistical significant 
difference (2= 14.4, p-value=0.001) between patients whowas reported as nonmalignant 
findings in mammography to have a diagnostic delay more thanpatient who was reported 
as malignant findings. In addition, the study revealed that patient who was reported 
wrongly as nonmalignant findings in mammography was exposed to diagnostic delay 8 
times more than who was reported as malignant findings. 
Moreover, the result of U/S affected thediagnosticdelay in that patientswho have been 
reported as nonmalignant findings in U/Shad a diagnostic delay more than those who have 
been reportedasmalignantfindings. Also, the result revealed that patient who was wrongly 
reported as nonmalignant findings in U/S was exposed to diagnostic delay more than 
patient with malignant finding (2= 7.4, p-value=0.018). In addition, the study revealed 
that patient who was reported wrongly as nonmalignant findings in U/S is exposed to 
diagnostic delay 3.7 times than those who was reported as malignant findingsas shown in 
the Table (4.16) 
The researcher interprets these results in that nonmalignant findings in either 
mammography or U/S may lead to three main scenarios: nonmalignant findings may be 
neglected, or treated as a breast disease rather than cancer, or finally patients may be 
scheduled in a close follow up program. All these management and follow up processes 
may delay the time of actual diagnosis.Therefore, nonmalignant findings in either 
mammography or U/S increase the delay time to diagnosis and the results are agree withthe 
literature(Norsa'adah et al., 2011;Ozmen et al., 2014) 
81 
4.2.4 Patients'accessibility todiagnostic services for breast cancer 
4.2.4.1 Accessibility of patients to mammography service with regards to the utilized 
sector 
 
Figure ‎4.6: Accessibility domains for mammography according to utilized sector 
 
Figure(4.6)clarifies a comparison between different sectors (governmental sector, 
NGOs,andthe private sector) regarding topatients' accessibility tomammography services 
and shows that the highest weighted mean score for physical accessibility & affordability 
domain (83%)is for governmental hospitals. This reflects the availability and affordability 
of mammography services in governmental hospitals. The highest weighted mean score 
regarding appointment&waiting time (90%)isfor NGOs. This high weighted mean score 
reflects that NGOs provides mammography service withinappropriateappointment and 
waiting time. Regarding communication&patient's respect domain, the highest weighted 
mean score is 79% for NGOs sector. 
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The researcher wanted to know if the weighted mean score for accessibility domains is 
statistically different between the three utilized sectors. For this purpose, the researcher 
performed one way ANOVA test as illustrated in Table (4.17). 
4.2.4.2 Differences between patients' accessibility to mammography service regarding 
the sector they utilized 
Table ‎4.17:Differences between patients' accessibility to mammography service and 
the sector they utilized 
p-value F Mean±SD N Category Domain 
0.172 1.80 
4.1 ± 0.6 30 
Governmental 
hospital 
Physical accessibility 
&affordability 3.9 ± 0.7 55 NGOs 
3.7 ± 0.9 6 Private 
.021* 
 
4.048 
 
4.1 ± 0.6 30 
Governmental 
hospital 
Appointment &waiting time 
 
4.5 ± 0.5 55 NGOs 
4.3 ± 0.5 6 Private 
.550 
 
.595 
 
3.9 ± 0.5 30 
Governmental 
hospital 
Communication &patient 
respect 4 ± 0.5 55 NGOs 
3.8 ± 0.4 6 Private 
 
*statistically significant 
Table (4.17)shows the ANOVA test which revealed no statistically significant difference 
between physical accessibility &affordability to mammography service and the three 
utilized sectors (p-value=0.172).Also, there are no statistically significant differences in 
patient's communication &respect with regards to the sector they utilized (p-value= 0.55). 
On the other hand, the test shows a statistically significant difference 
betweenappointment&waiting time domain for mammography exams between the three 
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sectors (F= 4.048, p-value = 0.021). To examine these differences, LSD post hoc test was 
performed and revealed thatthe governmental sector had the lowest mean score in the 
waiting time and appointment domain (mean= 4.1), followed by the private sector (mean= 
4.3) and the highestfor NGOs (mean= 4.5). The researcher interpretsthe results in that the 
crowded waiting list for mammography exam in the governmental hospitals makes the 
examination to be done at a longer appointment than that of NGOs and theprivate sector. 
On the other hand waiting time at the private sector score is slightly low as patients in the 
private sector have a higher expectation towards the service provided. Also, the score may 
be affected by the low sample size.Within in-depthinterviewsone of the radiologists said 
"patients utilizeda private sector has a higher expectation. Also, she went to the private 
sector considering the time factor. So, any delay will be considered"  
4.2.4.3 Patients'accessibility to U/Sservicewith regards to the utilized sector 
 
Figure ‎4.7: Accessibility domains for U/S according to utilizedsector 
 
The highest weighted mean score in the physical accessibility &affordability domain of 
U/S service is 83% for thegovernmental sector. This reflects the available, reachable and 
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affordable service at the governmental hospitals. The weighted mean scores for this 
domain is 77% for NGOs and the private sector as well. 
Regarding appointment and waiting time domain, the highest mean score is 92% for the 
private sector, followed by 87% and 83% for NGOs and the governmental hospitals 
respectively. Regarding communication and patient's respect domain, the researcher noted 
that the communication and patient's respect domain is almost equal at governmental, 
NGOs, and the private sector (73%, 75%, 75% respectively)asshown inFigure (4.7) 
The researcher concerned to know if there is a statistically significant difference between 
patients'accessibility forU/S serviceandthe utilized sectors. To achieve this purpose, the 
researcher performed one way ANOVA test.  
4.2.4.4 Differences between patients' accessibility to U/S service and the sector they 
utilized 
Table ‎4.18: Differences between patients' accessibility to U/S service and the sector 
they utilized 
p-value F Mean±SD N Category Domain 
 
.032* 
 
3.6 
4.2 ± 0.5 39 Governmental hospital 
Physical accessibility & 
affordability 
3.8 ± 0.6 47 NGOs 
3.9 ± 0.6 23 Private 
0.018* 
 
4.16 
 
4.2 ± 0.7 39 Governmental hospital 
Appointment &waiting 
time 
 
4.4 ± 0.6 47 NGOs 
4.6 ± 0.4 23 Private 
0.874 0.14 
3.7 ± 0.6 39 Governmental hospital 
Communication &patient 
respect 
3.7 ± 0.5 47 NGOs 
3.7 ± 0.6 23 Private 
 
*statistically significant 
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Table (4.18) shows the results of One way ANOVA test regarding U/S. Patients are 
different in their physical accessibility and affordability in relation to the sector they 
utilized and the difference reaches the statistically significant (F= 3.6, p-value= 0.032). 
LSD post hoc test shows that the highest mean score for physical accessibility 
&affordability domain is for patients performed their U/S at governmental hospitals 
(mean= 4.2), followed by theprivate sector (mean= 3.9), and NGOs (mean= 3.8). The 
researcher interprets this result in that the patient performed U/S in governmental hospitals 
canafford the service more than those performed it at NGOs or the private sector. In 
addition, screening programs at NGOs focus in mammography and perform U/S only for 
selective cases. Also, it was noted that patients utilized NGOs and the private sectorsuffer 
long distance and transportation issue impact if they are compared to those in the 
governmental hospitals.  
Considering appointment &waiting time domain for U/S service, one way ANOVA test 
revealed a statistically significant difference between thesector utilized and this domain 
(F= 4.16, p-value= 0.018). LSD post hoc test shows that the lowest mean score of this 
domain is for patients performed their U/S exam at governmental hospitals (mean= 4.2), 
followed by those performed it at NGOs (mean= 4.4) and finally the highest mean score 
for those performed the exam at the private sector (mean= 4.6). The researcher noted that 
the patients have a shorter appointment and waiting time if U/S is performed at NGOs and 
the private sector if compared to those performed it at governmental hospitals. 
About the communication and patient's respect domain, one way ANOVA test shows no 
statistically significant differences between communication&patient respect domain for 
U/S exam with regards to the center they utilized (p-value= 0.87). 
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4.2.4.5 Patients'accessibility to biopsy service with regards to the utilized sector 
 
Figure ‎4.8: Accessibility domains for biopsy according to utilized sector 
Figure (4.8) shows that the highest weighted mean score for physical accessibility 
&affordability domain (79%)is for patients conducted biopsy atNGOs, followed by 
weighted mean scores (76%) for patients utilized the private sector and governmental 
hospitals as well.  
Governmental hospitals provide mammography, U/S and biopsy services for health insured 
patients withcopayments. Also, UNRWA refers mammography to its screening program. 
Some NGOs provides mammography service free of charge in non-permanent screening 
campaigns. In addition, CFTA refer suspected BC cases to NGOs free of charge for all the 
diagnostic procedures. Significantly, NGOs and UNRWA provide mammography 
andsometimesU/S services free of charge, but they don’t cover the fees of biopsy. As a 
result, the patient either performs the biopsy out of pocket or performs it at a governmental 
hospital.  
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Regarding appointment &waiting time, the highest weighted mean score is 90% for 
patients utilized the private sector, 87% for patients utilized NGOs and finally 76% for 
patients utilized the governmental hospitals.Considering the third domain 
communication&patient respect domain, the figure shows that the highest weighted mean 
score is 79% for NGOs, 75% for the private sector, and finally 72% for governmental 
hospitals. 
4.2.4.6 Differences between patients' accessibility to biopsy service and the sector they 
utilized 
Table ‎4.19: Differences between patients'accessibility to biopsy service and the sector 
they utilized 
p-
value 
F Mean±SD N Category Domain 
0.40 0.91 
3.8 ± 0.7 35 Governmental hospital 
Physical accessibility & 
affordability 
3.9±0.5 40 NGOs 
3.8± 0.7 46 Private 
0.00* 13.03 
3.8 ± 0.9 35 Governmental hospital 
Appointment &waiting 
time 
4.4 ± 0.6 40 NGOs 
4.5 ± 0.5 46 Private 
0.03* 3.578 
3.6 ± 0.6 35 Governmental hospital 
Communication 
&patient respect 
4.0 ± 0.5 40 NGOs 
3.8 ± 0.5 46 Private 
 
*statistically significant 
To examine if there arestatistically significant differences between accessibilityscores and 
the utilized sector, the researcher performed ANOVA test(Table 4.19). The test revealed 
that there is no statistically significant difference between patients physical 
accessibility&affordability scoresregarding biopsy service and the sector they utilized (p-
value= 0.40). 
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Regarding appointment &waiting time domain, ANOVA test shows a significant 
difference inappointment and waiting timedomain score among patients with regards to the 
utilized sector (F= 13.03, p-value= 0.00). Post hoc test shows that patients utilized 
governmental hospitals have the lowest score in this domain (mean= 3.8), followed by 
NGOs (mean= 4.4) and the highest mean score for the private sector (mean= 4.5). The 
researcher interprets this result in that patient performed thebiopsy at a governmental 
hospital has two types of delay, anappointment for conducting the biopsy exam and the 
other appointment for receiving the final histopathology report and this may take more 
than a month. Patients confirmed this result in the open-ended question about barriers 
during diagnostic process and revealed that the long waiting list for biopsy in 
governmental hospitals forced them to do it at NGOs or the private sector. One of the 
patientssaid"The hospital gave mean appointmentafter 16 days for biopsy, I could not wait 
along this time, I wanted to be assured".Medical specialists in biopsy field confirmed that 
overload work and the few work days specialized for biopsyleadtothisdelayasone of the 
experts at a governmental hospital said: "The problem of biopsy appointment that we have 
a long waiting list as we have only one U/S instrument for biopsy guidance and one day is 
specialized also". 
Regarding communication &patients respect domain, the test revealedthatthereare 
statistically significant differences between patients in their level of 
communicationandpatient respect(F= 3.57, p-value= 0.03) with the highest mean score for 
NGOs (mean= 4.0), followed by the private sector(mean= 3.8), and finally for the 
governmental hospitals (mean= 3.6). LSD post hoc test shows that there is a statistically 
significant difference between governmental and NGOs, and between governmental and 
the private sector. The researcher noted that patients performed the biopsy at governmental 
hospitals had not been given enough time to explain their condition and there are no 
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feasible telephone contact with the biopsy centers in contrast to the private and NGOs 
sectors. 
 
4.2.5 Effectiveness of imaging diagnostic procedures 
Table ‎4.20: Results of diagnostic imaging examinations 
Variable Categories Frequency (%) 
Mammography report conclusion 
n= 82 
Malignant findings (84.1 )69  
Nonmalignant 
findings 
13 (15.9) 
U/S report conclusion 
n= 101 
Malignantfindings 94 (93.1) 
Nonmalignant 
findings 
7 (6.9) 
Using BI-RADS classification at 
mammography 
(n=87) 
Yes 26 (29.9) 
No 61 (70.1) 
Using BI-RADS classification at U/S 
(n= 107) 
Yes 25 (23.4) 
No 82 (76.6) 
 
After completion of the patients' records by communication with the patients themselves, 
classification of these reports was made. All patients performed imaging exams and 
biopsies within three months period were included in the analysis. Unlessall other patients 
that performed biopsies in a period of time exceed more than three months after imaging 
exams were not included in this analysis. 
Table (4.20)shows that mammography succeeded to diagnose 84.1 % of the total patients 
referred to mammography units and failed to diagnose about 15.9% of the referred cases as 
it reported the cases as either benign findings or normal. Considering U/S, it was effective 
to diagnose about 93.1% of all cancer cases and failed to diagnose 6.9% of the referred 
cases as they were reported to have either benign findings or normal.  
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Misdiagnosis of imaging may be related to different sensitivities (Berg et al., 2004; Fatima 
et al., 2015).Also, the literature showed that interpretation errors, technical and tumor 
factors may lead to misdiagnosis of BC(Kamal et al., 2007). 
The current study shows that only 29.9% of mammography reports and 23.4 %of U/S 
reports classified the lesions by using a standard classification (BI-RADS). Despite the 
advantages of BI-RADS classification system in reporting mammography and 
U/S(previously clarifiedin chapter 2, p: 27), it is not heavily used among radiologists in 
theGGs. Different specialists agreed that it is very useful to adoptone classification as one 
of them said"These categories help the surgeon to determine the next step", and the other 
said "it unifies readings and interpretation between radiologists", anotherspecialist said 
"We are not a big country to have different views of adopted standards and guidelines. We 
should encourage using one standard to be a national standard, BI-RADS classification is 
a good classification especially it is actually used inJordan, Egypt,and Arab Gulf".Also, 
another expert said" Recently, we started a training coursein interpretation of 
mammography and U/S funded by WHO. This program is targeting radiologists and will 
adopt the use of BI-RADS classification to unify the interpretation language at all health 
institutions in GGs along with the west bank". 
4.2.6 Differences between mammography and U/Sfindings 
The researcher interested to know if there is a difference between mammography and U/S 
results in the participant's group who underwent mammography and U/S in the same three 
months.For this purpose, the researcher performed chi square test (n=77participants)as 
indicated inTable (4.21). 
Table ‎4.21: Differancesbetween findings of mammography and U/S 
Variable 
Malignant 
findings 
n (%) 
Non-malignant 
findings 
n (%) 
2 
P-
value 
mammography 
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Variable 
Malignant 
findings 
n (%) 
Non-malignant 
findings 
n (%) 
2 
P-
value 
mammography 
U
/S
 
Malignant findings 
n (%) 
60 (98.4) 7 (43.8) 
35.8 0.06
€
 
Non-malignant findings 
n (%) 
1 (1.6) 9 (56.3) 
Total 
n (%) 
61(100) 16(100) 
 
*statistically significant,
€
MacNemar test 
 
MacNemartest revealed that there is a difference in the results of these two examinations, 
but the difference does not reach statistically significant (2= 35.8, p-value= 
0.06).Mammography and U/S are different in diagnosis of BC as7 (43.8 %)of 
correctlyreported as malignant findings byU/S werewronglyreported as nonmalignant 
findings by mammography.Also, 1 (1.6%) ofwrongly reported as nonmalignant finding in 
U/S was correctly reported as malignant finding in mammography.The superiority of U/S 
above mammography in diagnosis of BC in the GGs is related to several factors including 
unavailability of stereotactic biopsy guided mammography which is the method of choice 
when a lesion is suspected by mammography. Also, interpretation errors of 
mammography,lack of second readings procedures, technical factors, and machines limited 
sensitivities especially when analogue mammography is used instead of digitalized 
systems.These factors force health care providers to depend upon U/S as a diagnostic tool 
rather than mammography. As far as the researcher know, effectiveness of mammography 
and U/S are different in BCdiagnosis and the combination of the two methods increase 
theeffectiveness of diagnosis and the result in a line with the literature (Lalchan et al., 
2015; Tiwari et al., 2017).  
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Chapter5: Conclusion and Recommendations 
5.1 Conclusion 
Early diagnosis of breast cancer is defined as early identification of patients with 
symptoms without delay. This study was carried out to evaluate the utilized diagnostic 
imaging modalities for breast cancer in Gaza Governorates.  
The study mainly examined three interrelated parts that affect the provision of timely and 
accurate diagnosis of BC.The first part includes factors related to patients, the second one 
includes factors related to the system,and the third one is the potential delay. The study 
showed that the mean age of Gaza's women diagnosed with BC duringthe year 2017 was 
51.9 years with the most affected age groups (40-49), and (50-59). The majority of them 
(73.8%) have never been examined before. 
The study revealed that mammography and U/S are the most imaging methods commonly 
used to diagnose BC in GGs with no role to MRI.Without a doubt, all the suspected BC 
patients during the diagnostic process underwentbiopsy procedureto confirm their 
diagnosis. There are several choices for suspected cancer patients in GGs to be examined; 
one of them is through governmental hospitals with copayments. In addition, 
nonpermanent screening campaignsthrough UNRWA and some NGOs provide 
mammography services and U/Sfree of charge without covering the financial fees of 
biopsy.In contrast, CFTA referssuspected cancer patients to do the three exams at NGOs 
centers free of charge.  
Unfortunately, more than one-third of the participants conducted the imaging exams at one 
facility and changed the facility for thebiopsy because of long appointment and 
unavailability of the service. 
93 
The study revealed that all women utilized the diagnostic services afterappearance of BC 
symptoms. This reflects underutilization of screening programs in the GGs that women use 
the service only after the BC symptoms appeared.High percentage of women sought health 
care because of feeling a mass. Moreover, 78.7% of study participants had one or more 
barriers to seek health care after the symptom appeared.These barriers were divided into 
two main parts; the first part includes barriers related to the unawareness regarding the BC 
symptoms as considering the symptom was not serious, painless, and no main complaint. 
The study revealed that patients perceived such barriers have been delayed more than 
patients who did not and the differences are statistically significant. This result indicates a 
necessity for a health education program to educate women regarding signs and symptoms 
of BC and the importance of early presentation. 
The second part includesbarriers related to the health care system, the study revealed that a 
previous imaging and the result was free is a barrier to seek health care another time. We 
have to adopt a standard follow- up protocol with obvious guidelines to follow 
symptomatic women that previously reported to have benign or even normal findings. 
The study also showed that patients perceived highoverall accessibility scores regarding 
mammography, U/S, and biopsy, which are 82%, 80% 78%, respectively. In addition, the 
study examined patients' accessibility to diagnostic services with regards to the sector they 
utilized, the study showed statistically significant differences between physical 
accessibility & affordability domain regarding U/S service as patients performed U/S in the 
governmental hospitals afford the service more than those performed it at NGOs or the 
private sector. Moreover, patients perceived a lower score for the appointment& waiting 
time domain in governmental hospitals for the three diagnostic methods (mammography, 
U/S, and biopsy) and the difference is statistically significant if it is compared to those 
utilizedNGOs and the private sector. Too much effort should be done to shorten the long 
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waiting list for the diagnostic exam and especially biopsy at governmental hospitals and to 
increase the number of days specialized for this purpose in order to decrease the financial 
and psychological burden among BC patients. With regards to communication & patients 
respect domain, the study revealed a statistically significant difference between patients 
performed the biopsy at governmental hospitals have a lower score if compared to those 
performed it at NGOs or the private sector. 
About system factors, the study revealed that no national standard protocol is available to 
diagnose BC patients neither in the first methodselected according to age, nor in the 
ranking of the diagnostic exams.  
The majority of patients were referred to imaging centers within two weeks of seeking 
health care. This result reflects that patients' referral to imaging centers is good in general 
but there is still a need to put additional care about rare types of tumors such as Paget's 
disease and inflammatory carcinoma as it may be initially treated as other diseases rather 
than cancer.  
Mammography was effective to diagnose 84.1 % of examined participants and U/S was 
effective to diagnose 93.1% of the referred cases. Besides that, mammography and U/S 
showed a difference in their diagnosis of BC but the difference did not reach the 
statistically significant (2=35.8, p-value= 0.06), and the combination between the two 
methods increase the effectiveness towards the diagnosis.The study concludesthat U/S 
should be done in complementary to mammography despite its negative results especially 
in symptomatic patients.  
Significantly, the study showed that 9% of the participants were lost to follow up after 
benign findings in a previous breast imaging less than a year because of factors related to 
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patients such as ignorance or to the health care system such as the doctor did not advise the 
patient to come back.  
The study showed that only 29.9% of mammography reports and 23.4 %of U/S reports 
classified the lesions by using a standard classification. Thus, there is a need to adopt a 
standard protocol to follow up reported benign findings and the necessary to standardize 
the reporting methods in order to help specialists in their decisions regarding follow up and 
biopsy issues. 
The third part affecting BC diagnosis is the potential delay; the study showed that19.7 % of 
the study participants delayed to seek health care 3 months and more from the symptoms 
appearance. In addition, there were no statistically significant differences between patient's 
delay to seek health care and examined sociodemographic variables (place of residence, 
income, level of education, and the presence of family history of BC).  
Also, the study showed that12.3% of the participants experienced a diagnostic delay. 
Inferential analysis showed that age is the only examined sociodemographic variable 
affecting the diagnosticdelay in that women below 40 years old have a longer 
diagnosticdelay than those 40 years old and more,and the difference was statistically 
significant(p-value=0.045). Surely, care should be given to symptomatic patients 
regardless the age. Also, the study showed that the reported nonmalignant finding in either 
mammography or U/S was a factor to delay BC diagnosis. Absolutely, this result is 
attributed to weakness in the follow-upissue.  
In conclusion, Patients factors that hinder BC early diagnosis are underutilization of 
screening programs, lack of awareness about BC signs and symptoms and lack of patients' 
attention about follow up of previously reported nonmalignant findings. Diagnosticdelayis 
related to patient age at diagnosis as younger patient have more diagnostic delay than old, 
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and reported nonmalignant findings in any of the imaging procedures.In addition, 
appointment delay especially for biopsy is an issue to be considered. 
There is still a need to increase patients' awareness regarding breast cancer signs and 
symptoms and the benefits of early presentation and detection. Also, there is a need to 
unify guidelines for screening, diagnostic, and follow up procedures in order to assure the 
provision of timely and accurate diagnosis of breast cancer. 
5.2 Recommendations 
5.2.1 The study recommendations 
1. Adopt national program with clear and unify guidelines regarding the imaging method 
of choice in the BC initial diagnosisand what should be done for a suspected breast 
cancer. 
2. There is a need to adopt clear guidelines to follow up symptomatic women with 
previously reported benign or normal findings. 
3. Unifying the way of interpreting mammography and U/S examinations using a standard 
classification. 
4. Health education programabout BC symptoms and signs shouldbe introduced with 
specific strategies in order to shorten thepatients' delay and to increase women 
utilization for mammography screening programs. 
5. Perform U/S in complementary with mammography in order to increase the 
effectiveness oftheimaging services in BC diagnosis. 
6. Stereotactic biopsy procedure should be activated at MOH in order to conduct the 
biopsy for suspected lesions especially microcalcifications by mammography. 
7. Symptomatic patients should be given the complete investigationsfor the presence of 
BC diagnosis regardless their ages. 
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8. Decrease long waiting lists for diagnostic procedures especially biopsy in the 
governmental hospitals. 
9. Female health care providers including radiologists, technologists and nurses in breast 
imaging field should be trained and skilled in order to make the diagnostic process more 
accepted. 
10. There is a necessity to complete the medical records of oncology patients and to 
document cancer stage for every patient. 
11.  Too much effort should be done to enhance the communication between health 
providers and patients in order to increase the trust about the services provided and to 
enhance the follow up issue. 
5.2.2 Recommendations for further research 
1. Conduct a prospective study to examine the accuracy of mammography and U/S in 
breast cancer diagnosis in GGs. 
2. Conductresearch about factors leading to diagnostic errors (Interpretation errors, 
and technical factors). 
3. Conduct research to deeply explore social barriers that may affect seeking health 
care and hinder the early diagnosis of breast cancer. 
4. Conduct a comparative study to explore the effectiveness of mammography and 
U/S in governmental hospitals, NGOs, and the private sector. 
5. Conduct research exploring the relationship between diagnostic delay and stage of 
cancer. 
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Annexes 
Annex 1: Palestine map 
 
Source: Palestinian Central Bureau of Statistic 
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Annex 2: Gaza Strip Map 
 
Source: http://www.maps-of-the-world.net/maps-of-asia/maps-of-gaza-strip 
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Annex 3: TNM classification of breast cancer 
 
Source:https://cancerstaging.org/referencestools/quickreferences/Documents/BreastSmall.pdf  
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Annex 4: Interviewed questionnaire: English version 
A. Serial number: 
B. Oncology center:Al-RantesiH.Gaza European H. 
Patient name: 
ID number: 
Contact number: 
Date of the interview:// (day/month/year) 
A. First: Interviewed Questionnaire 
1. Personal Data 
1.1 Age �years 
1.2 Permanent place of residence 
 
� North Gaza  
�Gaza  
�Middle Zone 
�Khanyounis 
�Rafah 
1.3 Marital Status �Single  
�Married 
�Divorced 
�Widow 
1.4 Level of education �Illiterate 
�Primary school (1-6 classes) 
�Preparatory school (7-9 classes) 
�Secondary education (10-12 classes) 
�University education 
1.5 Number of children � 
1.6 
 
Are you working? 
 
� Yes 
� No 
 If yes, specify your job: ________________ 
1.7 Monthly average household 
income  
� 
1.8 Do you have a health insurance? � Yes 
� No 
 
 If yes, what is its type? 
�compulsory 
�israeli workers 
�Voluntary 
�MOSA 
�Other, Specify________________ 
 
 
 
 
2. Medical history  
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2.1 Do you have a family history of 
breast cancer? 
�No 
�Yes  
If yes, what is the relation? 
More than one option is possible 
�Mother  
�Sister  
�Daughter  
�Aunt  
�Grandmother 
�Second degree relative 
2.2 In which side the problem was? �RT breast 
� LT breast 
� Both 
2.3 What were the Signs and 
Symptoms at the time of 
diagnosis? 
Symptom Yes No 
�Breast mass  
�Mass under axilla 
�Pain 
�Tingling 
�Nipple discharge  
�Retracted nipple 
�Two breast are not equal 
in size or shape 
�Readiness  
�asymptomatic  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Others, Specify: ____________ 
2.4 What was the time interval 
between the appearance of signs 
and symptoms and seeking health 
care services?  
�____________ 
2.5 Answer with yes or no about 
barriers that may face you during 
the diagnostic process: 
 
 
 
 
 
 
� symptom was notserious 
�Shy demonstrating 
 symptoms tohealth care 
professionals  
� Lack of pain 
� No chief complaint 
� Stigma 
� Feared of results 
� diagnostic facility was too far 
� Complexity of referral system 
� Don’t know where to go 
� Service was not available 
� Fear of husband abandonment 
� I went to traditional healers  
� Cost of the exams 
�Transportation costs 
� Didn’t trust of health care system 
�Lack of female health care 
providers 
� My husband prevented me  
� Fear of exposure to radiation 
� Fear of pain related to the exams 
Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No 
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�I don’t able to organize my time  
� A previous doctor visit who did 
not take care of me 
� A previous examination and the 
results were free 
 For other reasons 
Specify, ________________ 
2.6 How long did it take for 
completion the diagnosis? 
(from seeking health care to be 
diagnose of BC) 
 
� 
 
2.7 Who encourage you to seek 
services? 
�My husband 
� Family  
�A screening program at a health facility 
� no one (Self) 
2.8 Referral doctor specialty for the 
first diagnostic modality 
�PHC GP 
�Surgeon 
� Oncologist 
�Gynecologist 
� Radiologist 
�UNRWA 
�Screening program at NGOs  
Others, Specify _____________ 
2.9 How many times did you counsel 
health care providers before 
starting diagnostic process? 
�times 
2.10 Which exam(s) did you do during 
the diagnostic process? 
 (more than one answer is 
possible) 
�mammography  
� U/S 
�MRI 
�Biopsy  
2.11 Please, order the exams that have 
been performed to you during the 
diagnostic process,, 
(1, 2, 3, 4) 
 
�Mammography 
� U/S 
� combined mammography and U/S 
�MRI 
�Biopsy 
2.12 Have you ever been examined 
before? 
�No(If answer is no, move to question number 
(3.1) 
�Yes 
�No 
If yeas (for what reason?) 
�Screening 
�Diagnostic 
2.13 What was the exam (Exams) 
done? 
�Mammography  
�U/S 
�Biopsy 
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2.14 When did you have a previous 
examination? 
� 
 
2.15 What was the result? �Normal 
�Benign findings 
�Calcifications 
2.16 Where did you perform the 
previous examination (s)? 
�Governmental hospital 
� NGOs  
� Private sector 
 
3. Accessibility and Affordability data 
3.1 How many times did you visit the 
hospital or clinic to complete the 
diagnostic process?  
�times 
 
3.2 Did you receive a financial 
support from anyone to complete 
the diagnostic process? 
� No 
�Yes 
Specify whom? 
3.3 Did you change the facility during 
the diagnostic process? 
� No 
�Yes 
If yes, for what diagnostic exam? 
�Mammography 
�U/S 
�MRI 
�Biopsy 
3.4 What was the reason for changing 
the diagnostic facility? 
 
--------------------------------------------- 
4. General Questions about the diagnostic modalities 
4.1 During the diagnostic process, Where did you do the exams? 
Mammography 
 
U/S 
 
MRI 
 
Biopsy 
 
�Yes         �No �Yes         �No �Yes         �No �Yes         �No 
�Governmental h. 
�NGOs 
�NGOs with free 
breast exam  
�Private sector 
�Governmental h. 
�NGOs 
�NGOs with free 
breast exam  
�Private sector 
�Governmental h. 
�NGOs 
�NGOs with free 
breast exam  
�Private sector 
�Governmental h. 
�NGOs 
�NGOs with free 
breast exam  
�Private sector  
 
4.2 
 
Why did you choose this sector to perform the exam? 
Mammography U/S MRI Biopsy 
1-more affordable 
2- No long 
appointment 
3- Trust 
4- More quality  
5- doctor advise 
6- health insurance  
1-more affordable 
2- No long 
appointment 
3- Trust 
4- More quality  
5- doctor advise 
6- health insurance  
1-more affordable 
2- No long 
appointment 
3- Trust 
4- More quality  
5- doctor advise 
6- health insurance  
1-more affordable 
2- No long 
appointment 
3- Trust 
4- More quality  
5- doctor advise 
6- health insurance  
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7- One of my family 
members advice 
8. Availability of the 
service 
9. It is close to my 
Place of residence 
10.Society referral 
11. UNRWA referral 
7- One of my family 
members advice  
8. Availability of the 
service 
9. It is close to my 
Place of residence 
10.Society referral 
11. UNRWA referral 
7- One of my family 
members advice  
8. Availability of the 
service 
9. It is close to my 
Place of residence 
10.Society referral 
11. UNRWA referral 
7- One of my family 
members advice  
8. Availability of the 
service 
9. It is close to my 
Place of residence 
10.Society referral 
11.UNRWA referral 
4.3 How many days did you wait to perform the exams? ( Appointment) 
Mammography U/S MRI Biopsy 
    
4.4 How much did you pay for the diagnostic exams? 
Mammography U/S MRI Biopsy 
() NIS () NIS () NIS () NIS 
4.5 
 
How much did you pay to transportation for diagnostic 
facilities? (Including all visits for all exams) 
() NIS 
4.6 In general what is your 
satisfaction about the 
quality level of the 
service provided? 
Mammogra
phy 
1. less than 
accepted 
2.accepted 
3. good 
4.Excellent 
U/S 
 
1. less than 
accepted 
2.accepted 
3. good 
4.Excellent 
MRI 
 
1. less than 
accepted 
2.accepted 
3. good 
4.Excellent 
Biopsy 
 
 
1. less than 
accepted 
2.accepted 
3. good 
4.Excellent 
4.7 Will your recommend 
this service to one of 
your friends or family 
if it is needed? 
�Yes 
�No 
�Yes 
�No 
�Yes 
�No 
�Yes 
�No 
 
 
 
 
 
 
 
4.8 What are perceived barrierthat could hinder your diagnostic process? 
 
--------------------------------------------- --------------------------------------------- 
--------------------------------------------- --------------------------------------------- 
4.9 Did you have any suggestion that could enhance the quality of the services provided? 
 
--------------------------------------------- --------------------------------------------- 
 
--------------------------------------------- --------------------------------------------- 
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D
o
m
a
in
 
N
o
. 
Statement 
Mammogra
phy 
U/S 
 
MRI 
 
 
Biopsy 
 
1.Strongly 
disagree 
2.Disagree 
3.Uncertain 
4.agree 
5.strongly 
agree 
1.Strongly 
disagree 
2.Disagree 
3.Uncertain 
4.agree 
5.strongly 
agree 
1.Strongly 
disagree 
2.Disagree 
3.Uncertain 
4.agree 
5.stronglyagree 
1.Strongly 
disagree 
2.Disagree 
3.Uncertain 
4.agree 
5.strongly 
agree 
P
h
y
si
ca
l 
A
cc
es
si
b
il
it
y
 a
n
d
a
ff
o
rd
a
b
il
it
y
 
 
1. 
It was easy to reach 
to the center 
    
2. 
The distance between 
your place of 
residence and the 
facility was suitable 
 
   
3. 
Transportation was 
availableto the 
diagnostic facility 
    
4. 
In general, the 
performance of 
health care providers 
was good 
    
5. 
The cost of the exam 
was reasonable for 
you 
    
6. 
The transportation 
cost to reach the 
hospital was suitable 
    
A
p
p
o
in
tm
en
t 
a
n
d
 w
a
it
in
g
ti
m
e 
 
7. 
The referral systemto 
diagnostic facility 
was within 
appropriate time 
    
8. 
Theappointment to 
conduct the exam 
was suitable for you 
    
9. 
Health care 
providers committed 
with the 
appointments 
    
10 
Waiting time to get 
the service was 
appropriate 
    
11. 
The results of 
medical imaging 
exam were received 
at anappropriate time 
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12. 
Health care provider 
introduced him/ her- 
self before 
conducting the exam 
    
13. 
Medical imaging 
procedure was 
explained by the 
health care provider 
    
14. 
Health care provider 
answered your 
questions carefully 
    
15. 
Clean gownand 
coverlet were 
available 
    
16. 
Privacy was valued 
during imaging 
procedure 
    
17. 
There were female 
health care providers 
    
18. 
You were given 
enough time to 
explain your 
condition 
    
19. 
No discrimination 
between patients 
    
20. 
Feasible contact with 
the diagnostic 
facility 
    
Thanks for your cooperation 
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 noisrev cibarA -eriannoitseuq deweivretnI :5 xennA
_______________ : اٌشلُ اٌّزغٍغً-ة_______________سلُ اٌٍّف اٌطجٟ-  أ
غضح الأٚسٚثٟ .اٌشٔز١غ١ُ. َ: ِشوض الأٚساَ .ج
:   الاعُ
:  سلُ اٌٙٛ٠خ
 ________________:خٛاي_______________ سلُ اٌزٍ١فْٛ 
عٕخ /شٙش /٠َٛ / /: ربس٠خ اٌّمبثٍخ 
  إسخباَت يغ انًرَض: أولا
  انًؼهىياث انشخصُت.  1  
 1.1 اٌؼّش �
 شّبي غضح  �
  غضح�
 اٌٛعطٝ �
 خبٔ١ٛٔظ �
  سفر�
 ِىبْ اٌغىٓ اٌذائُ 
 
 2.1
 أغخ�
 ِزضٚخخ �
ِطٍمخ �
  أسٍِخ�
 3.1 اٌسبٌخ الاخزّبػ١خ
أِٟ �
 ) طفٛف6-1 (اثزذائٟ �
 ) طفٛف9- 7( إػذادٞ�
) 21-01( ثبٔٛٞ�
  رؼٍ١ُ خبِؼٟ�
 4.1 ػذد عٕٛاد اٌزؼٍ١ُ  
 5.1 ػذد الأؽفبي �
 ٔؼُ�
لا �
 إرا وبٔذ الإخبثخ ٔؼُ 
 ________________زذدٞ ػٍّه؟ 
 6.1 ً٘ رؼٍّ١ٓ؟
 7.1 ِب ٘ٛ ِزٛعؾ اٌذخً اٌشٙشٞ ٌلأعشح  �
 ٔؼُ�
 لا�
إرا ٔؼُ زذد ٔٛػٗ ؟ 
ػبًِ إعشائ١ً �إخجبسٞ�
رأِ١ٓ شؤْٚ اخزّبػ١خ �اخز١بسٞ�
________________  : أخشٜ زذدٞ 
 
 8.1 ً٘ ٌذ٠ىٟ ربِ١ٓ طسٟ؟ 
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   انخارَخ انطبٍ. 2
 لا�
  ٔؼُ�
أكثر يٍ إجابت  (را ٔؼُ ِب ٟ٘ دسخخ اٌمشاثخإ
) واحذة يًكُت
أَ �
أخذ �
ثٕذ �
خبٌخ أٚ ػّخ  �
خذح �
 لشاثخ ِٓ اٌذسخخ اٌثبٔ١خ�
 1.2 ً٘ ٌذ٠ىٟ ربس٠خ ػبئٍٟ ٌغشؽبْ اٌثذٞ؟
 اٌثذٞ الأ٠ّٓ�
اٌثذٞ الأ٠غش �
 وٍ١ّٙب�
 2.2 فٟ أٞ خٙخ اٌّشىٍخ؟
 3.2 ِبالأػشاع اٌز١ظٙشد ٌذ٠ىٟ ػٕذ ثذا٠خ اٌّشع؟  الأػشاع ٔؼُ لا
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
وزٍخ فٟ اٌثذٞ �
وزٍخ رسذ الإثؾ �
أٌُ �
ٚخض �
إفشاص ِٓ اٌسٍّخ  �
زٍّخ غبئشح �
شؼشد ثأْ اٌثذ٠١ٓ غ١ش �
ِزغبٚ٠١ٕفٟ اٌسدُ أٚ اٌشىً 
ازّشاس �
 ثذْٚ أػشاع� 
 ____________أػشاع أخشٜ زذدٞ�
ِب ٟ٘ اٌّذح اٌضِٕ١خ ث١ٓ ظٙٛس الأػشاع ٚؽٍت   ____________�
 اٌّغبػذح اٌطج١خ؟
 4.2
 لا
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ٔؼُ
 
 
 
 
 
 
 
 
 
 
 
 
 
 
الأػشاع غ١ش اػزجشد أْ �
 خط١شح
اٌسشج ِٓ اٌىشف ػٍٝ �
 أخظبئ١١ٓ
لا ٠ٛخذ أٌُ �
 لا ٠ٛخذ ػشع سئ١غٟ�
اٌشؼٛس ثبٌؼ١ت �
اٌخٛف ِٓ إٌزبئح �
ِىبْ اٌزشخ١ض ثؼ١ذ  �
اٌزؼم١ذاد فٟ ػٍّ١خ اٌزسٛ٠ً �
ٌُ أػشف أ٠ٓ أرٛخٗ �
اٌخذِخ غ١ش ِزٛفشح �
اٌخٛف ِٓ أْ ٠زشوٕٟ صٚخٟ �
رٛخٙذ إٌٝ اٌطت اٌجذ٠ً �
رىٍفخ اٌفسٛطبد ػبٌ١خ �
 رىٍفخ اٌّٛاطلاد ػبٌ١خ �
أخ١جٟ ثٕؼُ أٚ لا زٛي اٌّؼ١مبد اٌزٟ لذ رىْٛ 
ٚاخٙزه ػٕذ ثذا٠خ ظٙٛس الأػشاع ٚلشاس اٌٍدٛء 
 اٌٝ اٌشػب٠خ اٌظس١خ؟
 5.2
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لا أثك ثبٌٕظبَ اٌظسٟ �
ػذَ ٚخٛد ِمذِبد خذِخ �
 )ٔغبء(
ِٕؼٕٟ صٚخٟ �
 اٌخٛف ِٓ اٌزؼشع ٌلأشؼخ  �
 اٌخٛف ِٓ الأٌُ اٌّظبزت �
ٌٍفسض 
 ٌُ أعزطغ رٕظ١ُ ٚلزٟ ٌٍز٘بة �
ٌٍفسض 
ٌمذ صسد اٌطج١ت ِغجمب ٌُٚ �
٠جذٞ أٞ ا٘زّبَ ثسبٌزٟ 
لّذ ثئخشاء فسٛطبد ِغجمخ �
 ٚوبٔذ إٌزبئح ؽج١ؼ١خ
ِؼ١مبد أخشٜ زذدٞ 
 ____________
ِٕز ثذا٠خ (وُ ِٓ اٌّذح اعزغشلذ ػٍّ١خ اٌزشخ١ض؟ �
 .)ؽٍجه ٌٍشػب٠خ اٌظس١خ ٚززٝ رّبَ اٌزشخ١ض
 6.2
 اٌضٚج�
اٌؼبئٍخ �
 سٚخٛد ثشٔبِح اٌىشف اٌّجه�
 لا ازذ�
 7.2 ِٓ اٌزٞ شدؼىٟ ٌزٍمٟ اٌخذِخ اٌظس١خ؟
 
ؽج١ت اٌشػب٠خ الأٌٚ١خ �
 أخظبئٟ اٌدشازخ�
 أخظبئٟ الأٚساَ�
 أخظبئٟ ٔغبء ٚٚلادح�
 أخظبئٟ أشؼخ�
الأٚٔشٚا �
أزذ ثشاِح اٌّغر اٌخبطخ ثبٌثذٞ �
 ____________زذدٞ : أخشٜ�
ِب رخظض اٌطج١ت أٚ ِٓ ٟ٘ اٌدٙخ اٌزٟ لبِذ 
 ثزسٛ٠ٍه ٌؼًّ اٌفسٛطبد اٌخبطخ ثزظٛ٠ش اٌثذٞ؟
 8.2
ػبٍِ١ٓ فٟ اٌّدبي لّزٟ ثبعزشبسحوُ ِٓ اٌّشاد ِشح�
 اٌظسٟ ٚأخظبئ١١ٓ ٌزجذأػٍّ١خ اٌزشخ١ض؟
 9.2
 ِبِٛخشاَ�
أٌزشاعبٚٔذ �
 سٔ١ٓ ِغٕبؽ١غٟ �
  عست ػ١ٕخ �
اٌزٟ رُ ػٍّٙب )اٌزظٛ٠ش (ِب اٌفسٛطبد الإشؼبػ١خ 
 ٌىٟ؟
 )أكثر يٍ اجابت يًكُت (
 
 01.2
 ِبِٛخشاَ�
أٌزشاعبٚٔذ �
أٌزشاعبٚٔذ ِىًّ + ِبِٛخشاَ �
 سٔ١ٓ ِغٕبؽ١غٟ �
  عست ػ١ٕخ�
 )اٌزظٛ٠ش(ٌٛ عّسزٟ سرجٟ اٌفسٛطبد الإشؼبػ١خ 
: أثٕبء ػٍّ١خ اٌزشخ١ضاٌزٟ رُ ػٍّٙب ٌىٟ 
 )4,3,2,1(
 
 11.2
 )1.3إرا وبٔذ الإخبثخ لا أزمً ٌٍغؤاي سلُ ( لا�
 ٔؼُ �
) ؟ِب ٘ٛ عجت اٌزظٛ٠ش(إرا وبٔذ الإخبثخ ٔؼُ 
وشف ِجىش �
  رشخ١ض�
 21.2 ً٘ لّزٟ ثئخشاء فسٛطبد عبثمخ؟
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 ِبِٛخشاَ�
اٌزشاعبٚٔذ �
 ػ١ٕخ�
ٞ لّزٟ داي)اٌفسٛطبد اٌغبثمخ(ِب ٘ٛ اٌفسض 
 )٘ب(ثئخشاءٖ
 31.2
 41.2 ِزٝ رُ ػًّ اٌفسض اٌغبثك ٌىٟ ؟ �
  ؽج١ؼٟ�
 ٚسَ زّ١ذ �
 رىٍغبد�
 51.2 ِب ٟ٘ ٔز١دخ اٌفسظبٌغبثك ؟ 
  لطبع زىِٟٛ�
اٌمطبع غ١ش زىِٟٛ �
  اٌمطبع اٌخبص�
 61.2 أ٠ٓ رُ فسظه ف١بٌغبثك؟
  يؼهىياث انىصىل وانًقذرة ػهً دفغ يصارَف ػًهُت انخشخُص . 3
وُ ِشح صسرٟ ِشاوض اٌزشخ١ض لاعزىّبي  ِشح�
 ػٍّ١خ اٌزشخ١ض؟
 1.3
 ٔؼُ�
لا �
 _______:إرا وبٔذ الإخبثخ ٔؼُ زذد ٞ اٌدٙخ 
ً٘ رٍم١زٟ ِغبػذاد ِبٌ١خ ِٓ أٞ خٙخخلاي 
 ػٍّ١خ اٌزشخ١ض؟
 
 2.3
  ٔؼُ�
  لا�
إرا وبٔذ الإخبثخ ٔؼُ لأٞ فسض رُ اٌزغ١١ش 
ِبِٛخشاَ �
أٌزشاعبٚٔذ �
 سٔ١ٓ ِغٕبؽ١غٟ �
  عست ػ١ٕخ�
 3.3 ً٘ غ١شرٟ ِىبْ اٌفسظأثٕبء ػٍّ١خ اٌزشخ١ض؟
 
 ---------------------------------------------
 4.3 ِب اٌغجت اٌزٞ خؼٍه رغ١ش٠ٓ اٌّىبْ؟
 يؼهىياث ػايت حىنىسائم انخشخُص. 4
 1.4 أ٠ٓ ػٍّزٟ اٌفسٛطبد اٌزشخ١ظ١خ؟,فٟ خلاي ػٍّ١خ اٌزشخ١ض 
 ػ١ٕخ
 لا-ٔؼُ
 سٔ١ٓ ِغٕبؽ١غٟ
 لا-ٔؼُ
 )رٍفض٠ْٛ (أٌزشاعبٚٔذ 
 لا-ٔؼُ
 ِبِٛخشاَ
 لا-ٔؼُ
  اٌمطبع اٌسىِٟٛ�
 لطبع غ١ش زىِٟٛ �
 لطبع غ١ش زىِٟٛ �
 وشف  ثشٔبِح ِؼٛخٛد
ِدبٟٔ  
  لطبع خبص�
  اٌمطبع اٌسىِٟٛ�
 لطبع غ١ش زىِٟٛ �
 لطبع غ١ش زىِٟٛ �
 وشف  ثشٔبِح ِؼٛخٛد
ِدبٟٔ  
  لطبع خبص�
  اٌمطبع اٌسىِٟٛ�
 لطبع غ١ش زىِٟٛ �
 لطبع غ١ش زىِٟٛ �
 وشف  ثشٔبِح ِؼٛخٛد
ِدبٟٔ  
  لطبع خبص�
  اٌمطبع اٌسىِٟٛ�
 لطبع غ١ش زىِٟٛ �
 لطبع غ١ش زىِٟٛ �
 وشف  ثشٔبِح ِؼٛخٛد
ِدبٟٔ  
  لطبع خبص�
 2.4 ٌّبرا رُ اخز١بس ٘زا اٌّىبْ دْٚ غ١شٖ لإخشاء اٌفسض ؟
 ِبِٛخشاَ )رٍفض٠ْٛ (أٌزشاعبٚٔذ  سٔ١ٓ ِغٕبؽ١غٟ ػ١ٕخ
اعزطبػزٟ ششاء اٌخذِخ .1
 ِٓ اٌّىبْ
ِٛاػ١ذ اٌسدٛصاد .2
وبٔذ ِٕبعجخ 
اعزطبػزٟ ششاء اٌخذِخ .1
 ِٓ اٌّىبْ
ِٛاػ١ذ اٌسدٛصاد .2
وبٔذ ِٕبعجخ 
ٔظشا لاعزطبػزٟ ششاء .1
 اٌخذِخ ِٓ اٌّىبْ
ِٛاػ١ذ اٌسدٛصاد .2
وبٔذ ِٕبعجخ 
 ٔظشا لاعزطبػزٟ ششاء . 1
اٌخذِخ ِٓ اٌّىبْ 
ِٛاػ١ذ اٌسدٛصاد .2
وبٔذ ِٕبعجخ 
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أثك ثٙزا اٌّىبْ .3
خٛدح اٌخذِخ اٌّمذِخ فٟ .4
اٌّىبْ 
لبَ ؽج١جٟ ثزسٛ٠ٍٟ ٌٙزا .5
 اٌّىبْ
ٌٛخٛداٌزأِ١ٓ طسٟ .6
أزذ أفشاد ػبئٍزٟ .7
ٔظسٕ١جٗ 
ٌزٛفش اٌخذِخ فٟ . 8
اٌّىبْ  
ٌمشثٗ ِٓ ِىبْ عىٕٟ . 9
رسٌٛزّٓ اٌدّؼ١خ . 01
اٌخ١ش٠خ 
ِسٌٛخ ِٓ الأٚٔشٚا .11
 
أثك ثٙزا اٌّىبْ .3
خٛدح اٌخذِخ اٌّمذِخ فٟ .4
اٌّىبْ 
لبَ ؽج١جٟ ثزسٛ٠ٍٟ ٌٙزا .5
 اٌّىبْ
ٌٛخٛداٌزأِ١ٓ طسٟ .6
أزذ أفشاد ػبئٍزٟ .7
ٔظسٕ١جٗ 
ٌزٛفش اٌخذِخ فٟ . 8
 اٌّىبْ  
ٌمشثٗ ِٓ ِىبْ عىٕٟ . 9
رسٌٛزّٓ اٌدّؼ١خ . 01
اٌخ١ش٠خ 
 ِسٌٛخ ِٓ الأٚٔشٚا.11
أثك ثٙزا اٌّىبْ .3
خٛدح اٌخذِخ اٌّمذِخ فٟ .4
اٌّىبْ 
لبَ ؽج١جٟ ثزسٛ٠ٍٟ ٌٙزا .5
 اٌّىبْ
ٌٛخٛداٌزأِ١ٓ طسٟ .6
أزذ أفشاد ػبئٍزٟ .7
ٔظسٕ١جٗ 
ٌزٛفش اٌخذِخ فٟ . 8
اٌّىبْ  
ٌمشثٗ ِٓ ِىبْ عىٕٟ . 9
رسٌٛزّٓ اٌدّؼ١خ .01
اٌخ١ش٠خ 
 ِسٌٛخ ِٓ الأٚٔشٚا.11
أثك ثٙزا اٌّىبْ .3
خٛدح اٌخذِخ اٌّمذِخ فٟ .4
اٌّىبْ 
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Annex 6: Abstraction sheet 
Item Mammography U/S MRI 
1.1  Request date(day/month/year)    
1.2  Examination date(day/month/year)    
1.3  Report date(day/month/year)    
1.4  
Report conclusion 
1.Normal 
2.Benign findings 
3.Dense breast for other investigation 
4.Suspected Malignancy 
   
1.5  BI-RADS classification    
1.6  Next step    
1.7  
Is the examination requested for the 
patient in need? 
� Yes 
�No 
� Yes 
�No 
� Yes 
�No 
1.8  If the exam is not needed, explain why? 
 
 
 
1.9  Biopsy Date //(day/month/year) 
1.10  Histopathology Report Date //(day/month/year) 
1.11  Biopsy procedure 
� FNA 
� True cut 
� Both (FNA+ True cut) 
�Excision B. 
1.12  
How many biopsies were needed to 
confirm diagnosis? 
 
1.13  Cancer Type 
 
____________ 
1.14  Cancer stage 
� I 
� II 
� III 
� IV 
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Annex 7: Semi structured in-depth interviews questions- English  version 
Introduction and explaining research purpose and the scenario of the interview 
For all specialists at hospitals and GPs at PHC 
 Is there a standard protocol to refer suspected BC cancer patients to diagnosis, if it 
is available what does it contain? 
 The quantitative data resulted in a difference between physician referral of 
patients to the first method according to their age. Is there a standard protocol that 
physicians depend on when referring suspected BC cancer? 
 From your point of view, what are the reasons that lead to delay in seeking health 
care after the appearance of BC signs and symptoms? 
 There are some cases that counseled health care providers more than threeor four 
times at PHC and specialists without referral to imaging, what is your opinion 
especially in the presence of screening programs free of charge and availability in 
the governmental hospitals? 
 The quantitative data of the current study resulted in a diagnosticdelay among BC 
patients less than 40 years old than those 40 years old and more: What is your 
opinion? 
For Radiologists, surgeonsand oncologists  
 At the current study, the results showed that radiologist use BI- RADS 
classification in 29.9% of mammography reports and 23.4% of U/S reports which 
indicates that this classification is not common among radiologists. What is your 
opinion? Do you encourage them to use this classification? 
 Some cases have benign findings in mammography, U/Sand even biopsy.After a 
period of time, these patients diagnosed withBC. In your opinion, what are the 
reasons for this phenomenon? 
 Some patients claimed that theyhavemasses since more than 3 years and they did 
not seek health careuntil they wereaccidently diagnosed to have BC during routine 
investigation for any other disease. Is there a probability for this mass to be cancer 
without performing any complication: What is your comment? 
For radiologists only 
 It is noted that there is no role for MRI in diagnosis BC and the diagnosis depends 
on mammography and U/S, what is your comment about that? 
130 
 Quantitative part of this study revealed that physical accessibility & affordability 
domain, and waiting time & appointment is very good in general, but there is a 
problem in the communication & patients respect domain. How do you explain 
the low score in this domain? 
 The study revealed that waiting time in theprivate sector is more than NGOs: How 
do you explain this result? 
For oncologists only 
 It is noted that 42.4% of mammography reports and 37.3% of U/S reports are not 
found in the patient file: How do you find this? 
 Quantitative data revealed that more than half of the study sample is not classified 
according to the cancer stage despite completeness of all investigations and 
starting the management process: How do you comment about this? 
For histopathologists only 
 Quantitative data resulted in that the mean of delay for the delivery of 
histopathology reports exceed 11 days: from you perspectives what are the 
reasons of such delays? 
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 noisrev cibarA -snoitseuq sweivretni htped-ni derutcurts imeS :8 xennA
 weivretni eht fo oiranecs eht dna esoprup hcraeser gninialpxe dna noitcudortnI
 وأطباء انرػاَت الأونُت  فٍ انًسخشفُاثنجًُغ الأخصائٍُُ
ً٘ ٠ٛخذ ٌذ٠ٕب فٟ ٚصاسح اٌظسخ ٌٚذٜ ِمذِٟ اٌخذِبد اٌظس١خ ثشٚرٛوٛي ٚاػر فٟ ػٍّ١خ  
رسٛ٠ً اٌّشػٝ اٌز٠ٓ ٌذ٠ُٙ أػشاع عشؽبْ اٌثذٞ ٌٍزشخ١ض؟ إرا ٚخذ ٘زا اٌجشٚرٛوٛي ِب ٘ٛ 
فسٛاٖ؟ 
أظٙشد ٔزبئح اٌذساعخ اٌىّ١خ أْ ٕ٘بن إخزلاف فٟ إخز١بس ٔٛع اٌزظٛ٠ش الأٚي ٌذٜ اٌّشػٝ ِغ  
ِب ٘ٛ اٌّم١بط اٌزٞ ٠غزٕذ ػٍ١ٗ الأؽجبء ػٕذ إخز١بس اٌفسض ًٚ٘ ٠ٛخذ . الأخز ثبلإػزجبس اٌؼّش
ثشٚرٛوٛي ِؼ١ٓ ٌزٌه؟ 
ِٓ ٚخٙخ ٔظشوُ ِب ٟ٘ الأعجبة اٌزٟ رؤدٞ إٌٝ رأخش اٌغ١ذاد فٟ ثؼغ الأز١بْ ػٓ ؽٍت  
اٌشػب٠خاٌظس١خ ثؼذ ظٙٛس أػشاع عشؽبْ اٌثذٞ؟ 
ٕ٘بن ثؼغ ِٓ اٌسبلاد رزٛخٗ ٌلإعزشبسح اٌطج١خأوثش ِٓ ثلاثأٚ أسثغ ِشاد فٟ ثؼغ ِشاوض  
 فٟ ظً ٚخٛد طبً  ِب سأ٠ىُ فٟ رٌه خظٛ,اٌشػب٠خ الاٌٚ١خ ٚأخظبئ١١ٓ دْٚ رسٛ٠ٍٙب ٌٍزظٛ٠ش
ثؼغ ثشاِح اٌّغر ٚ رٛفش اٌخذِخ فٟ اٌّغزشف١بد اٌسىِٛ١خ؟  
 04 أْ إٌغبء اٌّظبثبد ثغشؽبْ اٌثذٞ ٚػّشُ٘ ألً ِٓ  اٌىّ١خٌمذ أظٙشد ٔزبئح اٌذساعخ 
 ِبسأ٠ىُ؟: عٕخٌذ٠ُٙ ٚلذ رشخ١ض أؽٛي ِٓ اٌغ١ذاد فٟ ػّش الأسثؼ١ٓ عٕخ فأوثش
لأخصائٍُ الأشؼت وانجراحت والأوراو 
ِٓ رمبس٠ش % 4.32 ِٓ رمبس٠ش اٌّبِٛخشاَ ٚ %9.92أظٙشد إٌزبئح اٌىّ١خ ٌٍذساعخ أْ 
؟ ٚ٘زا ٠ؼٕٟ أْ ٘زا اٌزظٕ١ف غ١ش ))SDAR-IBرظٕ١ف ْ الأٌزشاعبٚٔذإعزخذَ ف١ٙب الأخظبئ١ٟ
ِب سأ٠ىُ ثٙزٖ إٌغت ًٚ٘ رٕظسْٛ أخظبئ١ٟ الأشؼخ : ِزذاٚي وث١شا ث١ٓ أخظبئ١ٟ الأشؼخ
إػزّبد ٘زا اٌزظٕ١ف فٟ رمبس٠شُ٘ اٌخبطخ ثبٌثذٞ؟ 
ٕ٘بن ثؼغ اٌسبلاد وبْ اٌّبِٛخشاِٛالأٌزشاعبٚٔذ ٚززٝ اٌؼ١ٕخ ف١ٙب وزً زّ١ذح ٚثؼذ فزشح رُ  
؟ رٍه اٌظب٘شحثشأ٠ه ِب ٘ٛ اٌغجت فٟ , إوزشبفبٌغشؽبْ
عٕٛاد دْٚ  3ٕ٘بن إدػبء ِٓ لجً ثؼغ اٌغ١ذاد ثٛخٛد اٌىزٍخ اٌغشؽبٔ١خ اٌّىزشفخ ِٕزأوثش ِٓ  
ؽٍت اٌّغبػذح اٌطج١خ ٚأْ ٘ؤلاء اٌغ١ذاد رُ رشخ١ظُٙ ثغشؽبْ اٌثذٞ ػٕذِب ؽٍت اٌطج١ت ػًّ 
ً٘ ٠ّىٓ أْ رىْٛ ٕ٘بن وزٍخ : اٌّبِٛخشاَ ػٕذ اٌذخٛي ٌٍّشفٝ ٚػًّ فسٛطبد سٚر١ٕ١خ
ِب رؼٍ١مىُ ػٍٝ ٘زا : عٕٛاد دْٚ ػًّ أٞ ِؼبػفبد أٚ ِشىلاد أخشٜ3عشؽبٔ١خ لأوثش ِٓ 
ِش؟ لأا
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: لأخصائٍُ الأشؼت فقط
ٌمذ أظٙشد ٔزبئح اٌذساعخ أْ ٌ١ظ ٕ٘بن دٚسٌٍشٔ١ٓ اٌّغٕبؽ١غٟ فٟ رشخ١ض ِشع عشؽبْ  
 و١ف رؼٍمْٛ ػٍٝ ٘زا الأِش؟ ,اٌثذٞ ٚأْ الإػزّبد ٠ىْٛ فمؾ ػٍٝ الأٌزشاعبٚٔذٚاٌّبِٛخشاَ
ٌمذ أظٙشد ٔزبئح اٌذساعخ اٌىّ١خأْ أثؼبداٌسظٛي ػٍٝ اٌخذِخاٌزشخ١ظ١خ ِٓ ٔبز١خ اٌٛطٛي  
 ٌٚىٓ أظٙشد اٌذساعخ أْ ِٛػٛع اٌزٛاطً ٚإززشاَ خذاً اٌف١ض٠بئٟ ٚاٌّٛاػ١ذ ثشىً ػبَ خ١ذ 
ثُ رفغشْٚ رذٟٔ ٔغجخ اٌزٛاطً : اٌّشػٝ ٠شىً ألٍُٙ ٔغجخ ٟٚ٘ لا رزؼذٜ خ١ذ فٟ وً اٌّشاوض
 ؟ِغ اٌّشاوض اٌظس١خ ِٚمذِٟ اٌخذِبد
أظٙشد إٌزبئح اٌىّ١خ أْ الإٔزظبس ٌٍسظٛي ػٍٝ رمبس٠ش اٌّبِٛخشاِجبٌٕغجخ ٌٍّشاوض اٌخبطخ  
 ثّب رؼٍمْٛ ػٍٝ ٘زا الأِش؟: أوثش ِٓ اٌّشاوضغ١ش اٌسىِٛ١خ 
:  لأخصائٍُ الأوراو فقط
ِٓ رمبس٠ش  %3.73 ِٓ رمبس٠ش اٌّبِٛخشاَ ٚ %4.24ٌمذ ٌٛزع ِٓ خلاي اٌذساعخ أْ ِب ٔغجزٗ  
ِب ٘ٛ سأ٠ىُ فٟ ٘زا ؟ : الأٌزشاعبٚٔذ غ١ش ِٛخٛدح فٟ ٍِفبد اٌّشػٝ اٌز٠ٓ شٍّزُٙ اٌذساعخ
أظٙشد إٌزبئح اٌىّ١خ أْ أوثش ِٓ ٔظف ػ١ٕخ اٌذساعخ غ١ش ِظٕفخ ٌّشازً الأٚساَ سغُ إرّبَ خّ١غ  
و١ف رؼٍمْٛ ػٍٝ ٘زا الأِش؟ : اٌفسٛطبد اٌزشخ١ظ١ىخ ٚاٌجذء ثبٌؼلاج
لأخصائٍُ الأَسجت فقط 
ٌمذ أظٙشد إٌزبئح اٌىّ١خ أْ اٌّشخظبرفٟ ِشع عشؽبْ اٌثذٞ ٠ؼبْٔٛ ِٓ ِٛاػ١ذ ؽٛ٠ٍخ ٌدب٘ض٠خ اٌزمش٠ش 
ثشأ٠ىُ ِب ٟ٘ الأعجبة اٌزٟ ردؼً ٘زٖ : ٠ِٛب11إٌٙبئٟ ز١ث أْ ِزٛعطبٌّٛاػ١ذ فٟ اٌسىِٛخ رض٠ذ ػٓ 
 اٌّٛاػ١ذ ؽٛ٠ٍخ؟
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Annex 9: Helsinki approval 
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Annex 10: MOH (admin) approval 
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أختً الكرٌمة ؛؛؛ 
: أقوم بإجراء دراسة بعنوان- سميرة سليمان أبو الشيخ:نا الباحثةأ
قطاع تقٌٌم خدماتالتصوٌر التشخٌصٌة المتاحة لدى مرضى سرطان الثدي فً محافظات " 
" غزة
 مسار علم الأوبئةوعلٌه /وذلك استكمالا ًلمتطلبات الحصول على درجة الماجستٌر فً الصحة العامة 
فقد تم إعداد هذه الإستبانة بهدف جمع البٌانات وأرجو منك الإجابة على بنودها بدقة وموضوعٌة 
وصدق حٌث أن الوقت اللازم لتعبئتها لا ٌتعدى النصف ساعة مع العلم أنه تم اختٌارك بشكل 
المعلومات الواردة فٌها سوف تستخدم فقط لأغراض البحث العلمً  عشوائً للمشاركة بالدراسة وأننّ 
 .خذ القرارات المبنٌة على الحقائقأوذلك بهدف تحسٌن وتطوٌر الخدمات التشخٌصٌة و
. إننا نرحب بمشاركتك فً هذا الإستبانة لذا نرجو من حضرتك الإجابة على جمٌع الأسئلة قدرالإمكان
نه بإمكانك المشاركة أو الرفض أو الإنسحاب بأي وقت ولن ٌؤثر ذلك على الخدمات أمع العلم 
 .المقدمة لكً
 شاكرين على حسن تعاونك
 سميرة سليمان أبو الشيخ: الباحثة
 جامعة القدس
         6855517950
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Annex 12: List of experts (interviewees) 
Name Affiliation 
Radiologists 
Dr. Kamal Jabre Al Shifa hospital- MOH 
Dr. Mohammad Mattar Al Shifa hospital- MOH 
Dr. Marwan Matar Gaza European hospital- MOH 
Dr. Mohamed Alkanoa Al Shifa hospital- MOH 
Dr. WajdyJarbou Al Shifa hospital- MOH 
Surgeons 
Dr. Mohammed Al- Ron Al Shifa hospital- MOH 
Dr. RamyImara Al Shifa hospital- MOH 
Oncologists 
Dr. KhaledThabet Al-Rantesihospital- MOH 
Dr. Ahmed Shorafa Gaza European hospital- MOH 
Histopathologists 
Dr. Hosam Hamada Al Shifa hospital- MOH 
Dr. Fayeq Abu Rouk Gaza European hospital- MOH 
GPs 
Dr. AydaHelles PHC 
Dr. AlaaMatar PHC 
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Annex 13: List of experts (arbitrators) 
No. Name Affiliation 
1.  Dr. Bassam Abo Hamad Al- Quds University 
2.  Dr. Yahia Abed Al- Quds University 
3.  Dr. Khitam Abo Hamad Al- Quds University 
4.  Dr. Ahmed Najim Al Azhar University 
5.  Dr. SamyAlagha Al Azhar University 
6.  Dr. Kamal Jabre MOH 
7.  Dr. AymanAbuMustafa Palestine College of Nursing 
8.  Mr. AwnyUbeid MOH 
9.  Dr. AydaHelles MOH 
10.  Dr. IhabNaser Al Azhar University 
11.  Mr. WaelYousef MOH 
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